<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Hum Mutat</journal-id>
<journal-id journal-id-type="iso-abbrev">Hum. Mutat</journal-id>
<journal-id journal-id-type="doi">10.1002/(ISSN)1098-1004</journal-id>
<journal-id journal-id-type="publisher-id">HUMU</journal-id>
<journal-title-group>
<journal-title>Human Mutation</journal-title>
</journal-title-group>
<issn pub-type="ppub">1059-7794</issn>
<issn pub-type="epub">1098-1004</issn>
<publisher>
<publisher-name>John Wiley and Sons Inc.</publisher-name>
<publisher-loc>Hoboken</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">30184290</article-id>
<article-id pub-id-type="pmc">6240363</article-id>
<article-id pub-id-type="doi">10.1002/humu.23647</article-id>
<article-id pub-id-type="publisher-id">HUMU23647</article-id>
<article-categories>
<subj-group subj-group-type="overline">
<subject>Research Article</subject>
</subj-group>
<subj-group subj-group-type="heading">
<subject>Research Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>The intellectual disability‐associated CAMK2G p.Arg292Pro mutation acts as a pathogenic gain‐of‐function</article-title>
<alt-title alt-title-type="left-running-head">PROIETTI ONORI et al.</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" id="humu23647-cr-0001">
<name>
<surname>Proietti Onori</surname>
<given-names>Martina</given-names>
</name>
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-0360-2894</contrib-id>
<xref ref-type="aff" rid="humu23647-aff-0001">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="humu23647-aff-0002">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="humu23647-cr-0002">
<name>
<surname>Koopal</surname>
<given-names>Balwina</given-names>
</name>
<xref ref-type="aff" rid="humu23647-aff-0001">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="humu23647-cr-0003">
<name>
<surname>Everman</surname>
<given-names>David B.</given-names>
</name>
<xref ref-type="aff" rid="humu23647-aff-0003">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="humu23647-cr-0004">
<name>
<surname>Worthington</surname>
<given-names>Jessica D.</given-names>
</name>
<xref ref-type="aff" rid="humu23647-aff-0003">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="humu23647-cr-0005">
<name>
<surname>Jones</surname>
<given-names>Julie R.</given-names>
</name>
<xref ref-type="aff" rid="humu23647-aff-0003">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="humu23647-cr-0006">
<name>
<surname>Ploeg</surname>
<given-names>Melissa A.</given-names>
</name>
<xref ref-type="aff" rid="humu23647-aff-0001">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="humu23647-cr-0007">
<name>
<surname>Mientjes</surname>
<given-names>Edwin</given-names>
</name>
<xref ref-type="aff" rid="humu23647-aff-0001">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="humu23647-aff-0002">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="humu23647-cr-0008">
<name>
<surname>van Bon</surname>
<given-names>Bregje W.</given-names>
</name>
<xref ref-type="aff" rid="humu23647-aff-0004">
<sup>4</sup>
</xref>
<xref ref-type="aff" rid="humu23647-aff-0005">
<sup>5</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="humu23647-cr-0009">
<name>
<surname>Kleefstra</surname>
<given-names>Tjitske</given-names>
</name>
<xref ref-type="aff" rid="humu23647-aff-0004">
<sup>4</sup>
</xref>
<xref ref-type="aff" rid="humu23647-aff-0005">
<sup>5</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="humu23647-cr-0010">
<name>
<surname>Schulman</surname>
<given-names>Howard</given-names>
</name>
<xref ref-type="aff" rid="humu23647-aff-0006">
<sup>6</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="humu23647-cr-0011">
<name>
<surname>Kushner</surname>
<given-names>Steven A.</given-names>
</name>
<xref ref-type="aff" rid="humu23647-aff-0002">
<sup>2</sup>
</xref>
<xref ref-type="aff" rid="humu23647-aff-0007">
<sup>7</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="humu23647-cr-0012">
<name>
<surname>Küry</surname>
<given-names>Sébastien</given-names>
</name>
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-5497-0465</contrib-id>
<xref ref-type="aff" rid="humu23647-aff-0008">
<sup>8</sup>
</xref>
<xref ref-type="aff" rid="humu23647-aff-0009">
<sup>9</sup>
</xref>
</contrib>
<contrib contrib-type="author" corresp="yes" id="humu23647-cr-0013">
<name>
<surname>Elgersma</surname>
<given-names>Ype</given-names>
</name>
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-3758-1297</contrib-id>
<address>
<email>y.elgersma@erasmusmc.nl</email>
</address>
<xref ref-type="aff" rid="humu23647-aff-0001">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="humu23647-aff-0002">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author" corresp="yes" id="humu23647-cr-0014">
<name>
<surname>van Woerden</surname>
<given-names>Geeske M.</given-names>
</name>
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-2492-9239</contrib-id>
<address>
<email>g.vanwoerden@erasmusmc.nl</email>
</address>
<xref ref-type="aff" rid="humu23647-aff-0001">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="humu23647-aff-0002">
<sup>2</sup>
</xref>
</contrib>
</contrib-group>
<aff id="humu23647-aff-0001">
<label><sup>1</sup></label>
<named-content content-type="organisation-division">Department of Neuroscience</named-content>
<institution>Erasmus University Medical Center</institution>
<named-content content-type="city">Rotterdam</named-content>
<country>the Netherlands</country>
</aff>
<aff id="humu23647-aff-0002">
<label><sup>2</sup></label>
<named-content content-type="organisation-division">ENCORE Expertise Center for Neurodevelopmental Disorders</named-content>
<institution>Erasmus University Medical Center</institution>
<named-content content-type="city">Rotterdam</named-content>
<country>the Netherlands</country>
</aff>
<aff id="humu23647-aff-0003">
<label><sup>3</sup></label>
<named-content content-type="organisation-division">Greenwood Genetic Center</named-content>
<named-content content-type="city">Greenwood</named-content>
<named-content content-type="country-part">SC</named-content>
<country country="US">USA</country>
</aff>
<aff id="humu23647-aff-0004">
<label><sup>4</sup></label>
<named-content content-type="organisation-division">Department of Human Genetics</named-content>
<institution>Radboud University Medical Center</institution>
<named-content content-type="city">Nijmegen</named-content>
<country>the Netherlands</country>
</aff>
<aff id="humu23647-aff-0005">
<label><sup>5</sup></label>
<named-content content-type="organisation-division">Donders Institute for Brain</named-content>
<named-content content-type="organisation-division">Cognition and Behavior</named-content>
<institution>Radboud University Nijmegen</institution>
<named-content content-type="city">Nijmegen</named-content>
<country>the Netherlands</country>
</aff>
<aff id="humu23647-aff-0006">
<label><sup>6</sup></label>
<institution>Allosteros Therapeutics</institution>
<named-content content-type="city">Sunnyvale</named-content>
<named-content content-type="country-part">CA</named-content>
<country country="US">USA</country>
</aff>
<aff id="humu23647-aff-0007">
<label><sup>7</sup></label>
<named-content content-type="organisation-division">Department of Psychiatry</named-content>
<institution>Erasmus University Medical Center</institution>
<named-content content-type="city">Rotterdam</named-content>
<country>the Netherlands</country>
</aff>
<aff id="humu23647-aff-0008">
<label><sup>8</sup></label>
<named-content content-type="organisation-division">CHU Nantes</named-content>
<named-content content-type="organisation-division">Service de Génétique Médicale</named-content>
<institution>9 quai Moncousu</institution>
<named-content content-type="city">Nantes</named-content>
<country country="FR">France</country>
</aff>
<aff id="humu23647-aff-0009">
<label><sup>9</sup></label>
<named-content content-type="organisation-division">l'institut du thorax</named-content>
<named-content content-type="organisation-division">INSERM</named-content>
<named-content content-type="organisation-division">CNRS</named-content>
<institution>UNIV Nantes</institution>
<named-content content-type="city">Nantes</named-content>
<country country="FR">France</country>
</aff>
<author-notes>
<corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break></break>Geeske M. van Woerden, Wytemaweg 80, Ee1483, 3015 CN Rotterdam, the Netherlands.<break></break>Email: <email>g.vanwoerden@erasmusmc.nl</email><break></break>
Ype Elgersma, Wytemaweg 80, Ee1438a, 3015CN, Rotterdam, the Netherlands.<break></break>Email: <email>y.elgersma@erasmusmc.nl</email><break></break></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>19</day>
<month>9</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="ppub">
<month>12</month>
<year>2018</year>
</pub-date>
<volume>39</volume>
<issue>12</issue>
<issue-id pub-id-type="doi">10.1002/humu.2018.39.issue-12</issue-id>
<fpage>2008</fpage>
<lpage>2024</lpage>
<history>
<date date-type="received">
<day>02</day>
<month>3</month>
<year>2018</year>
</date>
<date date-type="rev-recd">
<day>30</day>
<month>8</month>
<year>2018</year>
</date>
<date date-type="accepted">
<day>02</day>
<month>9</month>
<year>2018</year>
</date>
</history>
<permissions>
<!--<copyright-statement content-type="issue-copyright"> &#x000a9; 2018 Wiley Periodicals, Inc. <copyright-statement>-->
<copyright-statement content-type="article-copyright">© 2018 The Authors. <italic>Human Mutation</italic> published by Wiley Periodicals, Inc.</copyright-statement>
<license license-type="creativeCommonsBy-nc">
<license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="file:HUMU-39-2008.pdf" xlink:type="simple"></self-uri>
<abstract>
<title>Abstract</title>
<p>The abundantly expressed calcium/calmodulin‐dependent protein kinase II (CAMK2), alpha (CAMK2A), and beta (CAMK2B) isoforms are essential for learning and memory formation. Recently, a <italic>de novo</italic> candidate mutation (p.Arg292Pro) in the gamma isoform of CAMK2 (CAMK2G) was identified in a patient with severe intellectual disability (ID), but the mechanism(s) by which this mutation causes ID is unknown. Here, we identified a second, unrelated individual, with a <italic>de novo</italic> CAMK2G p.Arg292Pro mutation, and used <italic>in vivo</italic> and <italic>in vitro</italic> assays to assess the impact of this mutation on CAMK2G and neuronal function. We found that knockdown of CAMK2G results in inappropriate precocious neuronal maturation. We further found that the CAMK2G p.Arg292Pro mutation acts as a highly pathogenic gain‐of‐function mutation, leading to increased phosphotransferase activity and impaired neuronal maturation as well as impaired targeting of the nuclear CAMK2G isoform. Silencing the catalytic site of the CAMK2G p.Arg292Pro protein reversed the pathogenic effect of the p.Arg292Pro mutation on neuronal maturation, without rescuing its nuclear targeting. Taken together, our results reveal an indispensable function of CAMK2G in neurodevelopment and indicate that the CAMK2G p.Arg292Pro protein acts as a pathogenic gain‐of‐function mutation, through constitutive activity toward cytosolic targets, rather than impaired targeting to the nucleus.</p>
</abstract>
<kwd-group kwd-group-type="author-generated">
<kwd id="humu23647-kwd-0001">calcium/calmodulin‐dependent protein kinase type 2</kwd>
<kwd id="humu23647-kwd-0002">functional genomics</kwd>
<kwd id="humu23647-kwd-0003"><italic>in utero</italic> electroporation</kwd>
<kwd id="humu23647-kwd-0004">intellectual disability</kwd>
<kwd id="humu23647-kwd-0005">neurodevelopmental disorders</kwd>
<kwd id="humu23647-kwd-0006">neuronal arborization</kwd>
</kwd-group>
<funding-group>
<award-group>
<funding-source>National Institutes of Health</funding-source>
<award-id>5R01GM101277</award-id>
</award-group>
<award-group>
<funding-source>Nederlandse Organisatie voor Wetenschappelijk Onderzoek</funding-source>
<award-id>017.106.384</award-id>
<award-id>863.12.017</award-id>
<award-id>918.866.10</award-id>
</award-group>
</funding-group>
<counts>
<fig-count count="9"></fig-count>
<table-count count="0"></table-count>
<page-count count="17"></page-count>
<word-count count="10432"></word-count>
</counts>
<custom-meta-group>
<custom-meta>
<meta-name>source-schema-version-number</meta-name>
<meta-value>2.0</meta-value>
</custom-meta>
<custom-meta>
<meta-name>component-id</meta-name>
<meta-value>humu23647</meta-value>
</custom-meta>
<custom-meta>
<meta-name>cover-date</meta-name>
<meta-value>December 2018</meta-value>
</custom-meta>
<custom-meta>
<meta-name>details-of-publishers-convertor</meta-name>
<meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:version=5.5.3 mode:remove_FC converted:06.12.2018</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
<notes>
<p content-type="self-citation">
<mixed-citation id="humu23647-cit-0046" publication-type="journal">
<string-name>
<surname>Proietti Onori</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Koopal</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Everman</surname>
<given-names>DB</given-names>
</string-name>, et al. <article-title>The intellectual disability‐associated CAMK2G p.Arg292Pro mutation acts as a pathogenic gain‐of‐function</article-title>. <source xml:lang="en"/>Human Mutation. <year>2018</year>;<volume>39</volume>:<fpage>2008</fpage>–<lpage>2024</lpage>. <pub-id pub-id-type="doi">10.1002/humu.23647</pub-id>
<pub-id pub-id-type="pmid">30184290</pub-id></mixed-citation>
</p>
<fn-group>
<fn id="humu23647-note-0001">
<p>Communicated by María‐Jesús Sobrido</p>
</fn>
</fn-group>
</notes>
</front>
<body>
<sec id="humu23647-sec-0010">
<label>1</label>
<title>INTRODUCTION</title>
<p>Intellectual disability (ID), characterized by an IQ score of &lt;70 and moderate to severe limitations in adaptive functioning, often has a genetic cause. Next generation sequencing (NGS) offers a powerful diagnostic modality for undiagnosed ID patients. Currently, despite the recent identification of more than 700 genes associated with ID, in approximately half of ID cases, the genetic pathogenicity cannot be established with certainty, since the mutation has not been identified before (Vissers, Gilissen, &amp; Veltman, <xref ref-type="ref" rid="humu23647-bib-0042">2016</xref>).</p>
<p>Calcium/calmodulin‐dependent protein kinase type II (CAMK2) is a Ser/Thr protein kinase family consisting of four isozymes (CAMK2A, CAMK2B, CAMK2G, and CAMK2D). CAMK2A and CAMK2B have a highly abundant and neuron‐selective expression. Targeted deletion of CAMK2A or CAMK2B in mice has revealed their indispensable requirement for normal cognition (Borgesius et al., <xref ref-type="ref" rid="humu23647-bib-0002">2011</xref>; Elgersma et al., <xref ref-type="ref" rid="humu23647-bib-0008">2002</xref>; Giese, Fedorov, Filipkowski, &amp; Silva, <xref ref-type="ref" rid="humu23647-bib-0011">1998</xref>; Hell, <xref ref-type="ref" rid="humu23647-bib-0016">2014</xref>; Lisman, Schulman, &amp; Cline, <xref ref-type="ref" rid="humu23647-bib-0020">2002</xref>; Lisman, Yasuda, &amp; Raghavachari, <xref ref-type="ref" rid="humu23647-bib-0021">2012</xref>; Silva, Paylor, Wehner, &amp; Tonegawa, <xref ref-type="ref" rid="humu23647-bib-0034">1992a</xref>; Silva, Stevens, Tonegawa, &amp; Wang, <xref ref-type="ref" rid="humu23647-bib-0035">1992b</xref>; van Woerden et al., <xref ref-type="ref" rid="humu23647-bib-0041">2009</xref>). Moreover, human CAMK2A and CAMK2B mutations have recently been established as a cause of ID (Küry et al., <xref ref-type="ref" rid="humu23647-bib-0018">2017</xref>). In contrast to CAMK2A and CAMK2B, much less is known about the other CAMK2 isoforms, CAMK2G and CAMK2D. However, recently a <italic>de novo</italic> mutation in the <italic>CAMK2G</italic> gene (c.875G &gt; C p.Arg292Pro, henceforth denoted as CAMK2G<sup>Arg292Pro</sup>) was identified in a patient with severe ID (de Ligt et al., <xref ref-type="ref" rid="humu23647-bib-0005">2012</xref>). In addition, here, we describe a second, unrelated individual with ID carrying the c.875G &gt; C p.Arg292Pro mutation, strongly suggesting a causative role for CAMK2G in ID.</p>
<p>Even though the expression of CAMK2G in the adult brain is relatively low compared to CAMK2A and CAMK2B (Tobimatsu &amp; Fujisawa, <xref ref-type="ref" rid="humu23647-bib-0040">1989</xref>), CAMK2G is highly abundant in the developing nervous system in rats (Bayer, Löhler, Schulman, &amp; Harbers, <xref ref-type="ref" rid="humu23647-bib-0001">1999</xref>) and in humans, where it is the dominant isoform in the first trimester in the hippocampus (Figure <xref ref-type="fig" rid="humu23647-fig-0001">1</xref>A). Other than a few studies, reporting associations of common variation in CAMK2G with reduced memory performance (de Quervain &amp; Papassotiropoulos, <xref ref-type="ref" rid="humu23647-bib-0006">2006</xref>), depression (Li et al., <xref ref-type="ref" rid="humu23647-bib-0019">2013</xref>) and chronic inflammatory pain (Pan et al., <xref ref-type="ref" rid="humu23647-bib-0025">2014</xref>), and a recent study proposing that CAMK2G functions as a calcium/calmodulin (Ca<sup>2+</sup>/CaM) shuttle (Ma et al., <xref ref-type="ref" rid="humu23647-bib-0022">2014</xref>), the mechanistic function of CAMK2G during neurodevelopment has remained largely unknown.</p>
<fig fig-type="Figure" id="humu23647-fig-0001" orientation="portrait" position="float" xml:lang="en">
<label>Figure 1</label>
<caption>
<p>CAMK2G knockdown in primary hippocampal neurons results in increased arborization. (A) Expression levels of human CAMK2A, CAMK2B, CAMK2D, and CAMK2G in the hippocampus during gestation, showing that CAMK2G is the dominant isoform in the first trimester, and contributes substantially in the second and the third trimester. Data was extracted from the BrainSpan database (<ext-link ext-link-type="uri" xlink:href="https://www.brainspan.org/">https://www.brainspan.org/</ext-link>). (B) Representative confocal images of hippocampal neurons co‐transfected on DIV7 with combinations of control shRNA, with control vector or CAMK2G<sup>WT</sup> and an RFP plasmid or shRNA against <italic>Camk2g</italic> with control vector or CAMK2G<sup>WT</sup> and an RFP plasmid. Transfected neurons are identified by the RFP plasmid (red). See also Supplement 1 related to Figure <xref ref-type="fig" rid="humu23647-fig-0001">1</xref>. (C) Sholl analysis of neurite complexity. (D) Summary bar graphs of total neurite length and arborization measured for each condition and normalized to the control shRNA (total neurite length: one‐way ANOVA, <italic>F</italic>[3,82] = 8.42, <italic>P</italic> = 6.05E‐05; control vector+control shRNA vs. control vector+<italic>Camk2g</italic>‐shRNA, <italic>P</italic> = 0.0004; CAMK2G<sup>WT</sup>+control shRNA, <italic>P</italic> = 0.99; CAMK2G<sup>WT</sup>+<italic>Camk2g</italic>‐shRNA, <italic>P</italic> = 0.99; control vector+<italic>Camk2g</italic>‐shRNA vs. CAMK2G<sup>WT</sup>+control shRNA, <italic>P</italic> = 0.005; CAMK2G<sup>WT</sup>+<italic>Camk2g</italic>‐shRNA, <italic>P</italic> = 0.0002; CAMK2G<sup>WT</sup>+control shRNA vs. CAMK2G<sup>WT</sup>+<italic>Camk2g</italic>‐shRNA, <italic>P</italic> = 0.99; arborization: one‐way ANOVA, <italic>F</italic>[3,82] = 10.08, <italic>P</italic> = 1.00E‐05; control vector+control shRNA vs. control vector+<italic>Camk2g</italic>‐shRNA, <italic>P</italic> = 0.0001; CAMK2G<sup>WT</sup>+control shRNA, <italic>P</italic> = 0.99; CAMK2G<sup>WT</sup>+<italic>Camk2g</italic>‐shRNA, <italic>P</italic> = 0.99; control vector+<italic>Camk2g</italic>‐shRNA vs. CAMK2G<sup>WT</sup>+control shRNA, <italic>P</italic> = 0.0003; CAMK2G<sup>WT</sup>+<italic>Camk2g</italic>‐shRNA, <italic>P</italic> = 0.0005; CAMK2G<sup>WT</sup>+control shRNA vs. CAMK2G<sup>WT</sup>+<italic>Camk2g</italic>‐shRNA, <italic>P</italic> = 0.99)</p>
</caption>
<graphic id="nlm-graphic-3" xlink:href="HUMU-39-2008-g001"></graphic>
</fig>
<p>Here, we describe the clinical features of both individuals carrying the CAMK2G p.Arg292Pro mutation, the contribution of CAMK2G to neuronal migration <italic>in vivo</italic> and neuronal maturation <italic>in vitro</italic> and how the CAMK2G<sup>Arg292Pro</sup> mutation affects CAMK2G function. We found that reduced expression of CAMK2G leads to inappropriate precocious neuronal maturation. Moreover, we demonstrate that the p.Arg292Pro mutation is a pathogenic gain‐of‐function mutation, which renders the CAMK2G protein constitutively active, and causes a severe impairment of neuronal migration and maturation. Although the mutation also interferes with nuclear import, we found that the pathogenic effect we describe is not related to Ca<sup>2+</sup>/CaM shuttling. Taken together, our findings establish CAMK2G as a critical regulator of neurodevelopment and propose a novel mechanism by which the ID mutation, CAMK2G<sup>Arg292Pro</sup> exerts its pathogenic effect.</p>
</sec>
<sec id="humu23647-sec-0020">
<label>2</label>
<title>MATERIAL AND METHODS</title>
<sec id="humu23647-sec-0030">
<label>2.1</label>
<title>Identification of the CAMK2G p.Arg292Pro patients</title>
<p>Patient 1 was part of a whole‐exome sequencing study performed on patients with severe intellectual disability in Nijmegen, the Netherlands (de Ligt et al., <xref ref-type="ref" rid="humu23647-bib-0005">2012</xref>). Written consent for use of the patients’ photos were obtained from the parents. Patient 2 was identified by clinical whole‐exome sequencing done as part of a diagnostic evaluation through the Greenwood Genetic Center in South Carolina.</p>
</sec>
<sec id="humu23647-sec-0040">
<label>2.2</label>
<title>Constructs</title>
<p>The cDNA sequence from human <italic>CAMK2G<sup>WT</sup></italic> (NM_172171.2, variant without NLS) was obtained from a human brain cDNA library by PCR (Phusion high fidelity, Thermo Fisher) using the following primers: Fw 5′ ACATCTGGCGCGCCACCATGGCCACCACCGCCACCTG 3′ and Rev 5′ AAGTCCTTAATTAATTATCACTGCAGCGGTGCGGCAG 3′ and cloned into our dual promoter expression vector (<xref ref-type="supplementary-material" rid="humu23647-supl-0001">Suppl. Fig. S1</xref>). The cDNA sequence from rat <italic>CAMK2A<sup>WT</sup></italic> and <italic>CAMK2B<sup>WT</sup></italic> were kindly provided by Tobias Meyer and was cloned into our expression vector. The NLS version of <italic>CAMK2G<sup>WT</sup></italic> was generated using the following primers: Fw 5′ CGAGTTCCAGCGTGCACCTAATGCCACAGAGCAACAACAAAAACAGTCTCG 3′ and Rev 5′ CATTAGGTGCACGCTGGAACTCGACTTCCTTTTCTTGACACCGCCATCCGAC 3′. The p.Thr287Ala point mutation cDNA was synthesized by and ordered from GeneCust. The different point mutations were introduced with site‐directed mutagenesis (Invitrogen) using the following primers: <italic>CAMK2G</italic>–c.875G &gt; C (p.Arg292Pro), Fw 5′ CTGTGGAGTGTTTGCCCAAGTTCAATGCCCG 3′ and Rev 5′ CGGGCATTGAACTTGGGCAAACACTCCACAG 3′; <italic>CAMK2G</italic>–c.128A &gt; G (p.Lys43Arg), Fw 5′ ACGCAGGAGTACGCAGCAAGAATCATCAATACCAAGAAG 3′ and Rev 5′ GTATTGATGATTCTTGCTGCGTACTCCTGCGT 3′; <italic>CAMK2G</italic>–c.859‐860AC &gt; GA (p.Thr287Asp), Fw 5′ GCATCGTCAGGAGGATGTGGAGTGTTTG 3′ and Rev 5′ CAAACACTCCACATCCTCCTGACGATGC 3′; <italic>CAMK2G</italic>–c.916‐919ACGA &gt; GTGG (p.Thr306Val/Thr307Ala), Fw 5′ CTGAAGGGTGCCATCCTCGTGGCCATGCTTGTCTCCAGGA 3′ and Rev 5′ TCCTGGAGACAAGCATGGCCACGAGGATGGCACCCTTCAG 3′; <italic>CAMK2G</italic>–c.907‐909GCC &gt; AGA (p.Ala303Arg), Fw 5′ GAAAACTGAAGGGTAGAATCCTCACGACCAT 3′ and Rev 5′ ATGGTCGTGAGGATTCTACCCTTCAGTTTTC 3′. CAMK2G–c.1000T &gt; G (p.Ser334Ala), Fw 5′ GGTGTCAAGAAAAGGAAGGCGAGTTCCAGCGTGCACCT 3′ and Rev 5′ AGGTGCACGCTGGAACTCGCCTTCCTTTTCTTGACACC 3′. <italic>CAMK2A</italic>–c.871‐873 AAG &gt; CCT (p.Lys291Pro), Fw 5′ GGAGACCGTGGACTGCCTGCCTAAGTTCAATGCCAGGAGGA 3′ and Rev 5′ TCCTCCTGGCATTGAACTTAGGCAGGCAGTCCACGGTCTCC 3′; <italic>CAMK2B</italic>–c.874‐876AAG &gt; CCT (p.Lys292Pro), Fw 5′ GGAGACTGTGGAATGTCTGCCTAAGTTCAATGCAAGGAGGA 3′ and Rev 5′ TCCTCCTTGCATTGAACTTAGGCAGACATTCCACAGTCTCC 3′. The dual promoter expression vector was generated from the pCMV–<italic>tdTomato</italic> vector (Clonetech), where the <italic>CMV</italic> promoter was replaced with a <italic>CAGG</italic> promoter followed by a multiple cloning site (MCS) and transcription terminator sequence. To assure expression of the tdTOMATO independent from the gene of interest, a PGK promoter was inserted in front of the <italic>tdTomato</italic> sequence. For all the <italic>in vivo</italic> and <italic>in vitro</italic> experiments, the vector without a gene inserted in the MCS was taken along as control (control vector). shRNA constructs were obtained from the MISSION shRNA library for mouse genomes of Sigma Life Sciences and The RNAi Consortium (TRC). For knockdown of CAMK2G, we used three different shRNA plasmids, each targeting a different sequence: (1) GCCCGAGATCATCAGAAACTA, (2) CCTGAGGTCTTGAGGAAAGAT, and (3) CTACGCAGGAATATGCTGCAA. The control shRNA plasmid is the MISSION non‐target shRNA control vector: CAACAAGATGAAGAGCACCAA.</p>
</sec>
<sec id="humu23647-sec-0050">
<label>2.3</label>
<title>Mice</title>
<p>For the neuronal cultures, FvB/NHsD females were crossed with FvB/NHsD males (both ordered at 8–10 weeks old from Envigo). For the <italic>in utero</italic> electroporation, female FvB/NHsD (Envigo) were crossed with male C57Bl6/J (ordered at 8–10 weeks old from Charles River). All mice were kept group‐housed in IVC cages (Sealsafe 1145T, Tecniplast) with bedding material (Lignocel BK 8/15 from Rettenmayer) on a 12/12 h light/dark cycle in 21°C (±1°C), humidity at 40–70% and with food pellets (801727CRM(P) from Special Dietary Service) and water available <italic>ad libitum</italic>. All animal experiments were approved by the Local Animal Experimentation Ethical Committee, in accordance with Institutional Animal Care and Use Committee guidelines.</p>
</sec>
<sec id="humu23647-sec-0060">
<label>2.4</label>
<title>HEK‐293T cell transfections</title>
<p>To test the expression vector with the CAMK2 constructs, to measure the phosphorylation levels of CAMK2, and for immunoprecipitation (IP) experiments, we chose HEK‐293T cells, a cell line that is easy to transfect and culture. These cells were mycoplasma‐free but not authenticated. HEK‐293T cells were cultured in DMEM/10% Fetal Calf Serum (FCS)/1% penicillin/streptomycin in 6‐well plates (or 10 cm dishes for IP experiments) and transfected when 50% confluent with the following DNA constructs: control vector, <italic>CAMK2G<sup>WT</sup></italic>, <italic>CAMK2G‐NLS<sup>WT</sup>, CAMK2G<sup>Arg292Pro</sup>, CAMK2G‐NLS<sup>Arg292Pro</sup>, CAMK2G<sup>Ala303Arg</sup>, CAMK2A<sup>WT</sup></italic>, <italic>CAMK2A<sup>Lys291Pro</sup></italic>, <italic>CAMK2B<sup>WT</sup></italic>, and <italic>CAMK2B<sup>Lys292Pro</sup></italic> (3 ug per 6‐well and 18 ug per 10 cm dish). Transfection of the plasmids was done using polyethylenimine (PEI) according to the manufacturer instructions (Sigma). Six to twelve hours after transfection, the medium was changed to reduce toxicity. Transfected cells were then used for western blot and Immunoprecipitation experiments.</p>
</sec>
<sec id="humu23647-sec-0070">
<label>2.5</label>
<title>Western blot</title>
<p>Two to three days after transfection, HEK cells were harvested and homogenized in lysis buffer (10 mM Tris‐HCl 6.8, 2.5% SDS, 2 mM EDTA), containing protease inhibitor cocktail (#P8340, Sigma), phosphatase inhibitor cocktail 2 (#P5726, Sigma) and phosphatase inhibitor cocktail 3 (#P0044, Sigma). Protein concentration in the samples was determined using the BCA protein assay kit (Pierce) and then lysate concentrations were adjusted to 1 mg/ml. Western blots were probed with primary antibodies against CAMK2G (C‐18; raised against the 478–495 C‐terminal peptide, 1:1000, sc‐1541, Santa Cruz; validated in this study by overexpression experiments), CAMK2A (6G9, 1:40.000, Abcam; validated in Elgersma et al. (<xref ref-type="ref" rid="humu23647-bib-0008">2002</xref>)), CAMK2B (CB‐β1, 1:10.000, Invitrogen; validated in van Woerden et al. (<xref ref-type="ref" rid="humu23647-bib-0041">2009</xref>)), Actin (MAB1501R, 1:20.000, Chemicon; validated in Antibodypedia (<ext-link ext-link-type="uri" xlink:href="https://Antibodypedia.com">https://Antibodypedia.com</ext-link>), Ph‐Thr286/Thr287 (auto‐phosphorylated CAMK2 antibody; #06‐881; 1:1000; Upstate Cell Signaling Solutions; validated in Elgersma et al. (<xref ref-type="ref" rid="humu23647-bib-0008">2002</xref>)) and RFP (#600401379, 1:2000, Rockland, validated in this study by overexpression experiments), and secondary antibodies (goat anti‐mouse (#926‐32210), goat anti‐rabbit (#926‐68021), and donkey anti‐goat (#926‐68074), all 1:15.000, LI‐COR). Blots were quantified using LI‐COR Odyssey Scanner and Odyssey 3.0 software.</p>
</sec>
<sec id="humu23647-sec-0080">
<label>2.6</label>
<title>Immunoprecipitation</title>
<p>Two to three days after HEK transfection in 10 cm dishes, cells were harvested in PBS and cell pellets were taken up in 500 ul of IP lysis buffer (20 mM Tris pH 8.0, 150 mM NaCl, 1% NP40) supplemented with protease inhibitor cocktail (#P8340, Sigma), phosphatase inhibitor cocktail 2 (#P5726, Sigma), and phosphatase inhibitor cocktail 3 (#P0044, Sigma). Protein concentration in the samples was determined using the BCA protein assay kit (Pierce) and 600 ug of total protein adjusted to a volume of 800 ul was used for immunoprecipitation. 20 ul of the total volume was saved as “input.” Cell lysates were incubated with 50 ul of prewashed 50 % slurry Protein A Sepharose CL‐4B beads (#17‐0780‐01, GE Healthcare) at 4°C for &gt;1 h. Beads were then isolated and discarded by spinning down samples at 1000 rpm for 1′. Lysates were placed in a new tube with 3 ul of mouse calmodulin antibody (C3545, Sigma) and allowed to mix overnight at 4°C. The next morning, lysates were incubated with 50 ul of prewashed 50% slurry Protein G Sepharose beads (#17‐0618‐01, GE Healthcare) at 4°C for &gt; 1 h. Beads were then washed 3× with cold lysis buffer and after final wash proteins were eluted adding 20 ul of 2× Laemmli sample buffer and boiling for 5′ at 95°C before processing by western blot.</p>
</sec>
<sec id="humu23647-sec-0090">
<label>2.7</label>
<title>Primary hippocampal cultures</title>
<p>Primary hippocampal and cortical neuronal cultures were prepared from FvB/NHsD wild‐type mice according to the procedure described in Goslin and Banker (<xref ref-type="ref" rid="humu23647-bib-0012">1991</xref>). Briefly, hippocampi were isolated from brains of E16.5 embryos and collected altogether in 10 ml of neurobasal medium (NB, Gibco) on ice. After two washings with NB, the samples were incubated in pre‐warmed trypsin/EDTA solution (Invitrogen) at 37°C for 20 min. After 2× washing in pre‐warmed NB, the cells were resuspended in 1.5 ml NB medium supplemented with 2% B27, 1% penicillin/streptomycin, and 1% glutamax (Invitrogen), and dissociated using a 5 ml pipette. Following dissociation, neurons were plated in a small drop on poly‐d‐lysine (25 mg/ml, Sigma) coated 15 mm glass coverslips at a density of 1×10<sup>6</sup> cells per coverslip in 12 well plates containing 1 ml of supplemented NB for each coverslip. The plates were stored at 37°/5% CO<sub>2</sub> until the day of the transfection.</p>
</sec>
<sec id="humu23647-sec-0100">
<label>2.8</label>
<title>Neuronal transfection and immunocytochemistry</title>
<p>Neurons were transfected after 7 days <italic>in vitro</italic> (DIV) with the following DNA constructs: control vector (1.8 ug per coverslip), <italic>CAMK2G<sup>WT</sup></italic>, <italic>CAMK2G<sup>Arg292Pro</sup></italic>, <italic>CAMK2G<sup>Lys43Arg</sup></italic>, <italic>CAMK2G<sup>Lys43Arg/Arg292Pro</sup></italic>, <italic>CAMK2G<sup>Thr287Ala</sup>, CAMK2G<sup>Thr287D/Thr306Val/Thr307Ala</sup></italic>, <italic>CAMK2G<sup>Ala303Arg</sup>, CAMK2G‐NLS<sup>WT</sup></italic>, <italic>CAMK2G‐NLS<sup>Arg292Pro</sup>, CAMK2G‐NLS<sup>Ser334Ala</sup>, CAMK2G‐NLS<sup>Ser334Ala/Arg292Pro</sup>, CAMK2G‐NLS<sup>Lys43Arg/Arg292Pro</sup>, CAMK2A<sup>WT</sup></italic>, <italic>CAMK2A<sup>Lys291Pro</sup></italic>, <italic>CAMK2B<sup>WT</sup></italic>, and <italic>CAMK2B<sup>Lys292Pro</sup></italic> (all 2.5 ug per coverslip) or for knockdown experiments with a pool of the CAMK2G shRNAs with an RFP plasmid (Addgene) or the control shRNA with an RFP plasmid (all in total 4 ug per coverslip). Lipofectamine 2000 was used to transfect neurons, according to the manufacturer instructions (Invitrogen). For the neuronal morphology analysis, neurons were fixed 5 days post‐transfection with methanol and 4% paraformaldehyde (PFA)/4% sucrose, when stained for CAMK2G and 4% paraformaldehyde/4% sucrose, when stained for CAMK2A or CAMK2B and incubated overnight at 4°C with primary antibodies in GDB buffer (0.2% BSA, 0.8 M NaCl, 0.5% Triton X‐100, 30 mM phosphate buffer (PB), pH 7.4). To measure level of knockdown of CAMK2G and protein localization, neurons were fixed 5 days post‐transfection with methanol and 4% paraformaldehyde/4% sucrose and stained for CAMK2G, but for morphological analysis neurons were fixed with 4% paraformaldehyde/4% sucrose and processed without staining for CAMK2G. The following primary antibodies were used: MAP2 (1:500, #188004, Synaptic System, validation can be found on the manufacturers website: <ext-link ext-link-type="uri" xlink:href="https://www.sysy.com/products/map2/ref.php">https://www.sysy.com/products/map2/ref.php</ext-link>), CAMK2G (C‐18, 1:100, Santa Cruz), CAMK2A (6G9, 1:200, Abcam), CAMK2B (CB‐β1, 1:100, Invitrogen). For secondary antibodies, anti‐mouse‐Alexa488 (#715‐545‐150), anti‐goat‐Alexa488 (#705‐545‐003), and anti‐guinea‐pig‐Alexa647 (#706‐605‐148) conjugated antibodies (all 1:200, Jackson ImmunoResearch) were used. For the localization experiments, neurons were also stained with 4′,6‐diamidino‐2‐phenylindole solution (DAPI, 1:10000, Invitrogen) for 15′ before being mounted on glass. Slides were mounted using Mowiol‐DABCO (Sigma) mounting medium. Confocal images were acquired using a LSM700 confocal microscope (Zeiss).</p>
<p>For the analysis of the neuronal transfections, at least 10 confocal images (20× objective, 0.5 zoom, 1024 × 1024 pixels) of different transfected neurons (identified by the red staining) were taken from each coverslip for each experiment with at least two independent replications. For the analysis of the neuronal morphology, the NeuronJ plugin for ImageJ software was used to trace the dendrites with their branches. Total neurite length and arborization were measured and analyzed. All values were normalized against the mean value for each parameter of the control (control vector). Sholl analysis for the <italic>in vitro</italic> knockdown experiment was performed by counting the number of neurite intersections between the traced neurons and a series of concentric circumferences at an interval of 10 um from each other with the center on the soma. For the analysis of the protein levels upon shRNA transfection, the “Measure RGB” plugin from ImageJ software was used to measure the intensity of the fluorescent signal of the transfected cell, which was normalized against non‐transfected cells on the same coverslip and then normalized against the mean value of control shRNA transfected cells. For the analysis of the protein localization experiments, the DAPI staining was used to identify the nucleus and define a region of interest (ROI). To measure the intensity of the fluorescent signal relative to the protein of interest of the ROI nucleus and the ROI cytoplasm of each transfected cell, we used the “Measure” plugin of Fiji software. The intensity signal (Integrated density) was corrected for the area of the ROI and the background signal by using the following formula: IntDen–(area of the ROI × mean fluorescence of background reading). The ratio of the nucleus/cytoplasm corrected intensity value for each construct was averaged and normalized against the averaged ratio of the WT of the same neuronal batch. Analysis was done by an experimenter blinded for the transfection conditions.</p>
</sec>
<sec id="humu23647-sec-0110">
<label>2.9</label>
<title>In utero electroporation</title>
<p>The procedure was performed in pregnant FvB/NHsD mice at E14.5 of gestation to target mainly the progenitor cells giving rise to pyramidal cells of the layer 2/3 (Saito, <xref ref-type="ref" rid="humu23647-bib-0030">2006</xref>; Taniguchi, Young‐Pearse, Sawa, &amp; Kamiya, <xref ref-type="ref" rid="humu23647-bib-0039">2012</xref>). The DNA construct (1.5–3 ug/ul) was diluted in fast green (0.05%) and injected in the lateral ventricle of the embryos while still <italic>in uterus</italic>, using a glass pipette controlled by a Picospritzer III device. To ensure the proper electroporation of the injected DNA constructs (1–2 ul) into the progenitor cells, five electrical square pulses of 45 V with a duration of 50 ms per pulse and 150 ms inter‐pulse interval were delivered using tweezer‐type electrodes connected to a pulse generator (ECM 830, BTX Harvard Apparatus). The electrodes were placed in such a way that the positive pole was targeting the developing somatosensory cortex. The following plasmids were injected: control vector, <italic>CAMK2G<sup>WT</sup></italic>, <italic>CAMK2G<sup>Arg292Pro</sup></italic>, <italic>CAMK2G<sup>Lys43Arg</sup></italic>, <italic>CAMK2G<sup>Lys43Arg/Arg292Pro</sup></italic>, <italic>CAMK2G<sup>Thr287Ala</sup>, CAMK2G<sup>Thr287Asp/Thr306Val/Thr307Ala</sup></italic>, <italic>CAMK2G<sup>Ala303Arg</sup>, CAMK2G‐NLS<sup>WT</sup></italic>, <italic>CAMK2G‐NLS<sup>Arg292Pro</sup></italic>, <italic>CAMK2G‐NLS<sup>Lys43Arg/Arg292Pro</sup>, CAMK2A<sup>WT</sup></italic>, <italic>CAMK2A<sup>Lys291Pro</sup></italic>, <italic>CAMK2B<sup>WT</sup></italic>, and <italic>CAMK2B<sup>Lys292Pro</sup></italic> or for knockdown experiments: a pool of the CAMK2G shRNAs with an RFP plasmid (Addgene) or the control shRNA with an RFP plasmid. After birth, pups (M/F) were sacrificed at P18‐P22 for histochemical processing.</p>
</sec>
<sec id="humu23647-sec-0120">
<label>2.10</label>
<title>Immunohistochemistry</title>
<p>Mice were deeply anesthetized with an overdose of Nembutal and transcardially perfused with 4% paraformaldehyde. Brains were extracted and post‐fixed in 4% PFA. Brains were then embedded in gelatin and cryoprotected in 30% sucrose in 0.1 M phosphate buffer, frozen on dry ice, and sectioned using a freezing microtome (40–50 μm thick). Free‐floating coronal sections were washed in 0.1 M PB and a few selected sections were counterstained with 4′,6‐diamidino‐2‐phenylindole solution (DAPI, 1:10,000, Invitrogen) before being mounted with Mowiol on glass. Overview images of the coronal sections were acquired by tile scan imaging using a LSM700 confocal microscope (Zeiss) with a 10× objective. Zoom in images of the targeted area were taken using a 20× objective.</p>
<p>For the migration analysis, confocal images (10× objective, 0.5 zoom, 1024 × 1024 pixels) were taken from 2 to 3 non‐consecutive sections from at least three successfully targeted animals per plasmid. Images were rotated to correctly position the cortical layers, and the number of cells in different layers were counted using ImageJ (Analyze particles option), and the results were exported to a spreadsheet for further analysis. Cortical areas from the pia to the ventricle were divided in 10 equal‐sized bins and the percentage of tdTOMATO‐positive cells per bin was calculated.</p>
</sec>
<sec id="humu23647-sec-0130">
<label>2.11</label>
<title>Statistical analysis</title>
<p>All data was assumed to be normally distributed. Statistical difference between the conditions for the <italic>in vitro</italic> overexpression experiments was determined using one‐way analysis of variance (ANOVA) followed by Bonferroni's post‐hoc test for multiple comparisons and for the knockdown experiments using the two‐tailed unpaired <italic>t</italic>‐test (dual comparison). For the western blot analysis, one‐tailed and two‐tailed unpaired <italic>t</italic>‐test was used (dual comparison). For the <italic>in vivo</italic> experiments on neuronal migration, the analysis was performed on the number of targeted cells, measured as sum of the first four bins, considered to correspond to the layers 2/3 of the somatosensory cortex. Statistical analysis was performed using one‐way ANOVA, followed by Bonferroni's multiple comparison tests. Based on previous experiments performed in our lab, we considered that for the neuronal experiments <italic>in vitro</italic> at least two replicates, with 10 neurons each were necessary. For the western blot analysis, we considered at least three replicates, and for the IUE experiments, previous experiments in our laboratory showed that at least three targeted pups were necessary to draw any conclusion about the migration. <italic>P</italic>‐values are indicated in the figures with “*”: * indicates <italic>P</italic> &lt; 0.05, ** indicates <italic>P</italic> &lt; 0.01, *** indicates <italic>P</italic> &lt; 0.0001.</p>
</sec>
</sec>
<sec id="humu23647-sec-0140">
<label>3</label>
<title>RESULTS</title>
<sec id="humu23647-sec-0150">
<label>3.1</label>
<title>CAMK2G p.Arg292Pro mutation causes severe intellectual disability</title>
<p>Patient 1 carrying the CAMK2G p.Arg292Pro mutation has already briefly been described in a whole‐exome sequencing study describing several individuals with severe ID (de Ligt et al., <xref ref-type="ref" rid="humu23647-bib-0005">2012</xref>). Here, we identified a second, unrelated carrier of the heterozygous <italic>de novo</italic> CAMK2G p.Arg292Pro mutation (patient 2). He presented in infancy with generalized hypotonia and developmental delay and has remained hypotonic with markedly delayed gross motor and speech/language skills. He is currently diagnosed with severe ID and autism at 5 years of age. His physical exams have been notable for relative macrocephaly, prominent capillary vascular malformations on the forehead and glabella, minor dysmorphic facial features, and severe hypotonia. A detailed description of both patients is provided in <xref ref-type="supplementary-material" rid="humu23647-supl-0001">Suppl. Fig. S2</xref>. Both patients suffer from severe ID and severe hypotonia. They both have some facial dysmorphisms (<xref ref-type="supplementary-material" rid="humu23647-supl-0001">Suppl. Fig. S2</xref>), though not strikingly similar. By comparison, although individuals with mutations in CAMK2A or CAMK2B all suffer from ID and in most cases hypotonia, facial dysmorphisms are not commonly observed among individuals carrying mutations in CAMK2A or CAMK2B (Küry et al., <xref ref-type="ref" rid="humu23647-bib-0018">2017</xref>).</p>
<sec id="humu23647-sec-0160">
<label>3.1.1</label>
<title>Knockdown of CAMK2G causes increased neuronal arborization</title>
<p>Identifying two unrelated patients with a severe neurodevelopmental disorder carrying the same mutation in CAMK2G, strongly suggests that CAMK2G plays a role in neurodevelopment and neuronal functioning. However, whereas the indispensable roles of CAMK2A and CAMK2B for neuronal plasticity and cognitive function are well established, the neuronal function of CAMK2G remains poorly characterized. Considering the highly abundant expression of CAMK2G in the first trimester during which the nervous system starts to develop and the stable expression during the rest of the prenatal period (Figure <xref ref-type="fig" rid="humu23647-fig-0001">1</xref>A), we set out to investigate the role of CAMK2G during neuronal maturation <italic>in vitro</italic>, using shRNAs to effect knockdown of the CAMK2G protein. We transfected mouse primary hippocampal neurons with shRNAs directed against <italic>Camk2g</italic> or a control plasmid, together with a red florescent protein (RFP) reporter plasmid to visualize transfected neurons. Despite the CAMK2G antibody cross‐reactivity with CAMK2A and CAMK2B (<xref ref-type="supplementary-material" rid="humu23647-supl-0001">Suppl. Fig. S3</xref>), we nevertheless observed a 35% reduction of immunofluorescent signal 5 days after transfection, without any change in CAMK2A or CAMK2B levels (<xref ref-type="supplementary-material" rid="humu23647-supl-0001">Suppl. Fig. S3</xref>) consistent with a robust decrease specifically of CAMK2G. Transfection of <italic>Camk2g</italic> shRNA resulted in a substantial alteration of neuronal morphology, with a clear increase in the complexity of the neurite tree compared to the control condition, as measured by Sholl analysis (Figure <xref ref-type="fig" rid="humu23647-fig-0001">1</xref>C). Additional quantification of the neurite length and arborization revealed that neurons with reduced levels of CAMK2G exhibited a 38% increase in total neurite length and 55% increase of arborization compared to the control condition (Figure <xref ref-type="fig" rid="humu23647-fig-0001">1</xref>B and D, see figure legend for statistics). Mice express three CAMK2G isoforms, one of which contains a nuclear localization signal (NLS) (<xref ref-type="supplementary-material" rid="humu23647-supl-0001">Suppl. Fig. S4A</xref>). This isoform is present in both cytosol and nucleus and was recently proposed to shuttle Ca<sup>2+</sup>/CaM into the nucleus (Ma et al., <xref ref-type="ref" rid="humu23647-bib-0022">2014</xref>). In order to assess to what extent the observed effect on neurite length and arborization was specific for the down‐regulation of CAMK2G and whether there is differential contribution of the CAMK2G isoforms, we co‐transfected either the human CAMK2G isoform lacking the NLS (<italic>CAMK2G</italic>), the CAMK2G isoform containing the NLS (<italic>CAMK2G‐NLS)</italic>, <italic>CAMK2A</italic> or <italic>CAMK2B</italic> together with the shRNA against mouse <italic>Camk2g</italic>. Whereas co‐transfection of <italic>CAMK2A</italic> or <italic>CAMK2B</italic> with <italic>Camk2g</italic> shRNA had no effect on total neurite length (<xref ref-type="supplementary-material" rid="humu23647-supl-0001">Suppl. Fig. S4</xref>B and C), co‐transfection of <italic>CAMK2G</italic> or <italic>CAMK2G‐NLS</italic> with <italic>Camk2g</italic> shRNA both resulted in a complete rescue of the neuronal morphology phenotype caused by the down‐regulation of CAMK2G (Figure <xref ref-type="fig" rid="humu23647-fig-0001">1</xref>B–D and <xref ref-type="supplementary-material" rid="humu23647-supl-0001">Suppl. Fig. S4</xref>B and C). These results indicate that CAMK2G is indispensable for regulating neuronal morphology, but that this function does not require its nuclear import.</p>
</sec>
<sec id="humu23647-sec-0170">
<label>3.1.2</label>
<title>The CAMK2G<sup>Arg292Pro</sup> mutation is pathogenic both <italic>in vitro</italic> and <italic>in vivo</italic>
</title>
<p>To study the effect of the ID‐associated CAMK2G missense variant on neuronal function, we cloned the human <italic>CAMK2G</italic> gene with and without the c.875G &gt; C mutation in a dual promoter expression vector (see Section “Material and Methods”). Transfection of HEK‐293T cells with CAMK2G<sup>Arg292Pro</sup> achieved a 10‐fold lower CAMK2G protein signal compared to that achieved by transfection with CAMK2G<sup>WT</sup>, despite equal tdTomato levels, indicating that the p.Arg292Pro mutation affects protein stability (Figure <xref ref-type="fig" rid="humu23647-fig-0002">2</xref>A and B). Next, we investigated the effect of expression of CAMK2G<sup>WT</sup> and CAMK2G<sup>Arg292Pro</sup> in primary hippocampal neurons. Despite the reduced stability of CAMK2G<sup>Arg292Pro</sup>, levels of CAMK2G were increased in neurons transfected (tdTomato‐positive) with CAMK2G<sup>Arg292Pro</sup> (Figure <xref ref-type="fig" rid="humu23647-fig-0002">2</xref>C). Whereas expression of CAMK2G<sup>WT</sup> yielded no discernible morphological changes with respect to total neurite length or arborization, expression of CAMK2G<sup>Arg292Pro</sup> strongly reduced total neurite length as well as arborization, which was notably in the opposite direction as observed following <italic>Camk2g</italic> knockdown (Figure <xref ref-type="fig" rid="humu23647-fig-0002">2</xref>D). These results suggest that the p.Arg292Pro mutation functions as a pathogenic gain‐of‐function.</p>
<fig fig-type="Figure" id="humu23647-fig-0002" orientation="portrait" position="float" xml:lang="en">
<label>Figure 2</label>
<caption>
<p>CAMK2G<sup>Arg292Pro</sup> overexpression is severely disruptive for neurons <italic>in vitro</italic> and <italic>in vivo</italic>. (A) Representative western blot of CAMK2G<sup>WT</sup> or CAMK2G<sup>Arg292Pro</sup> (R292P) transfected HEK‐293T cells. (B) Quantification of the levels of CAMK2G expression, normalized against tdTOMATO in the different conditions (CAMK2G<sup>WT</sup> vs. CAMK2G<sup>Arg292Pro</sup>: <italic>t</italic>[10] = 16.62, <italic>P</italic> = 1.30E‐08, two‐tailed unpaired <italic>t</italic>‐test). (C) Representative confocal images of hippocampal neurons transfected on DIV7 with control vector (lacking CAMK2G), CAMK2G<sup>WT</sup> or CAMK2G<sup>Arg292Pro</sup>. See also Supplement 1 related to Figure <xref ref-type="fig" rid="humu23647-fig-0002">2</xref>. Transfected neurons are identified by the tdTOMATO (red). (D) Summary bar graphs of total neurite length and arborization measured for each condition and normalized to the control vector (total neurite length: one‐way ANOVA <italic>F</italic>[2,89] = 49.35, <italic>P</italic> = 3.79E‐15; control vector vs. CAMK2G<sup>WT</sup>, <italic>P</italic> = 0.9; CAMK2G<sup>Arg292Pro</sup>, <italic>P</italic> = 0.0001; CAMK2G<sup>Arg292Pro</sup> vs. CAMK2G<sup>WT</sup>, <italic>P</italic> = 0.0001; arborization: one‐way ANOVA <italic>F</italic>[2,89] = 31.8, <italic>P</italic> = 3.80E‐11; control vector vs. CAMK2G<sup>WT</sup>, <italic>P</italic> = 0.9; CAMK2G<sup>Arg292Pro</sup>, <italic>P</italic> = 0.0001; CAMK2G<sup>Arg292Pro</sup> vs. CAMK2G<sup>WT</sup>, <italic>P</italic> = 0.0001). (E) Representative images of P20‐P22 pups <italic>in utero</italic> electroporated at E14.5 with control vector, CAMK2G<sup>WT</sup> or CAMK2G<sup>Arg292Pro</sup> tdTOMATO positive cells indicate the successfully targeted neurons. DAPI (blue) counterstaining is used to identify general cortical structure. (F) Left: quantification of the neuronal migration pattern from the Layer 1 (L1) to the intermediate zone (IZ); Right: analysis of the percentage of targeted cells that reach the outer layers of the cortex measured as sum of bin 1–4 (one‐way ANOVA, <italic>F</italic>[2,20] = 58.88, <italic>P</italic> = 4.16E‐09; control vector vs. CAMK2G<sup>WT</sup>, <italic>P</italic> = 0.07; CAMK2G<sup>Arg292Pro</sup>, <italic>P</italic> = 0.0001; CAMK2G<sup>WT</sup> vs. CAMK2G<sup>Arg292Pro</sup>, <italic>P</italic> = 0.0001). Arrowheads indicate layer 2/3 of the somatosensory cortex, whereas the arrow indicates the subventricular zone (SVZ). Data in (B), (D), and (F) are presented as mean ± SEM. Numbers (<italic>X</italic>/<italic>Y</italic>) depicted in the bar graphs represent the number of samples (B), the total number of cells (<italic>X</italic>) and number of independent cultures (<italic>Y</italic>) (D) or the number of pictures (F) analyzed</p>
</caption>
<graphic id="nlm-graphic-5" xlink:href="HUMU-39-2008-g002"></graphic>
</fig>
<p>To evaluate the effect of CAMK2G<sup>Arg292Pro</sup> expression <italic>in vivo</italic>, we used <italic>in utero</italic> electroporation at E14.5. This assay measures the ability of targeted neural cells in the subventricular zone to successfully migrate to layer 2/3 of somatosensory cortex. This assay is very sensitive for changes that perturb normal neural cell function (Saito &amp; Nakatsuji, <xref ref-type="ref" rid="humu23647-bib-0031">2001</xref>; Tabata &amp; Nakajima, <xref ref-type="ref" rid="humu23647-bib-0037">2001</xref>; Taniguchi et al., <xref ref-type="ref" rid="humu23647-bib-0039">2012</xref>). Strikingly, cells expressing CAMK2G<sup>Arg292Pro</sup> exhibited a complete block of migration from the subventricular zone, despite more than 80% of the cells expressing CAMK2G<sup>WT</sup> having migrated normally to layer 2/3 of the somatosensory cortex (Figure <xref ref-type="fig" rid="humu23647-fig-0002">2</xref>E and F). These results further confirm the severe dominant effect of the p.Arg292Pro mutation on CAMK2G function.</p>
<p>Taken together these data suggest that although CAMK2G<sup>Arg292Pro</sup> has reduced protein stability, this mutation does not lead to a loss of function of CAMK2G, but instead appears to result in a paradoxical gain‐of‐function.</p>
</sec>
<sec id="humu23647-sec-0180">
<label>3.1.3</label>
<title>CAMK2G<sup>Arg292Pro</sup> has increased phosphotransferase activity</title>
<p>Considering that a gain‐of‐function mediates the effects of CAMK2G<sup>Arg292Pro</sup> and that the p.Arg292Pro mutation is located within the α‐helical auto‐regulatory domain of CAMK2G that maintains the kinase in an inactive state in the absence of Ca<sup>2+</sup>/CaM (Hudmon &amp; Schulman, <xref ref-type="ref" rid="humu23647-bib-0017">2002</xref>; Rellos et al., <xref ref-type="ref" rid="humu23647-bib-0029">2010</xref>), we hypothesized that the mechanism for the gain‐of‐function elicited by CAMK2G<sup>Arg292Pro</sup> might involve enhanced phosphotransferase or even constitutive activity. Therefore, we first assessed the level of Thr287 phosphorylation in HEK‐293T cells as readout for the phosphotransferase activity by expressing either CAMK2G<sup>WT</sup> or CAMK2G<sup>Arg292Pro</sup>. To allow for a direct comparison of their relative phosphorylation, we obtained equal protein levels by titrating the amount of transfected DNA. We found a significant increase of Thr287 phosphorylation in cells expressing CAMK2G<sup>Arg292Pro</sup> compared to CAMK2G<sup>WT</sup> (Figure <xref ref-type="fig" rid="humu23647-fig-0003">3</xref>A and B), suggesting that the p.Arg292Pro mutation enhances phosphotransferase activity and acts as a gain‐of‐function mutation.</p>
<fig fig-type="Figure" id="humu23647-fig-0003" orientation="portrait" position="float" xml:lang="en">
<label>Figure 3</label>
<caption>
<p>Overexpression of a dominant active form of CAMK2G is severely disruptive for neurons <italic>in vitro</italic> and <italic>in vivo</italic>. (A) Representative western blot of CAMK2G<sup>WT</sup> or CAMK2G<sup>Arg292Pro</sup> (R292P) transfected HEK‐293T cells. (B) Quantification of the levels of CAMK2G–Thr287 phosphorylation, normalized against total CAMK2G in the different conditions (<italic>t</italic>[10] = 2.29, <italic>P</italic> = 0.05 two‐tailed unpaired <italic>t</italic>‐test). (C) Representative confocal images of hippocampal neurons transfected on DIV7 with control vector, CAMK2G<sup>Lys43Arg</sup> (K43R), CAMK2G<sup>Ala303Arg</sup> (A303R) or CAMK2G<sup>Thr287Asp/Thr306Val/Thr307Ala</sup> (T287D/TT306‐7VA). Transfected neurons are identified by the tdTOMATO (red). (D) Summary bar graphs of total neurite length and arborization measured for each condition and normalized to the control vector (total neurite length: one‐way ANOVA, <italic>F</italic>[3,86] = 24.75, <italic>P</italic> = 1.23E‐11; control vector vs. CAMK2G<sup>Ala303Arg</sup>, <italic>P</italic> = 0.03; CAMK2G<sup>Lys43Arg</sup>, <italic>P</italic> = 0.99; CAMK2G<sup>Thr287Asp/Thr306Val/Thr307Ala</sup>, <italic>P</italic> = 0.0001; arborization: one‐way ANOVA, <italic>F</italic>[3,86] = 28.29, <italic>P</italic> = 8.03E‐13; control vector vs. CAMK2G<sup>Ala303Arg</sup>, <italic>P</italic> = 0.0003; CAMK2G<sup>Lys43Arg</sup>, <italic>P</italic> = 0.99; CAMK2G<sup>Thr287Asp/Thr306Val/Thr307Ala</sup>, <italic>P</italic> = 0.0001). (E) Representative images of P20‐P22 pups <italic>in utero</italic> electroporated at E14.5 with control vector, CAMK2G<sup>Lys43Arg</sup>, CAMK2G<sup>Ala303Arg</sup> or CAMK2G<sup>Thr287Asp/Thr306Val‐Thr307Ala</sup>. tdTOMATO positive cells represent neurons successfully targeted. DAPI (blue) counterstaining is used to identify general cortical structure. (F) Left: quantification of the neuronal migration pattern from the Layer 1 (L1) to the intermediate zone (IZ); Right: analysis of the percentage of targeted cells that reach the outer layers of the cortex measured as sum of bin 1–4 (one‐way ANOVA, <italic>F</italic>[3,32] = 56.92, <italic>P</italic> = 6.31E‐13; CAMK2G<sup>WT</sup> vs. CAMK2G<sup>Ala303Arg</sup>, <italic>P</italic> = 0.15; CAMK2G<sup>Lys43Arg</sup>, <italic>P</italic> = 0.99, CAMK2G<sup>Thr287Asp/Thr306Val/Thr307Ala</sup>, <italic>P</italic> = 0.0001). The dotted line represents the level reached by the CAMK2G‐WT (see Figure <xref ref-type="fig" rid="humu23647-fig-0002">2</xref>F for comparison). Arrowheads indicate layer 2/3 of the somatosensory cortex, whereas the arrow indicates the subventricular zone (SVZ). Data in (B), (D), and (F) are presented as mean ± SEM. Numbers (<italic>X</italic>/<italic>Y</italic>) depicted in the bar graphs represent the number of samples (B), the total number of cells (<italic>X</italic>) and number of independent cultures (<italic>Y</italic>) (D) or number of pictures (F) analyzed</p>
</caption>
<graphic id="nlm-graphic-7" xlink:href="HUMU-39-2008-g003"></graphic>
</fig>
<p>To further test whether the p.Arg292Pro mutation affects neuronal function by acting as a gain of function mutation, we first analyzed the effect of two mechanistically well‐established loss‐of‐function CAMK2 mutations on neuronal migration and morphology. The CAMK2G<sup>Ala303Arg</sup> mutation prevents binding of Ca<sup>2+</sup>/CaM, and therefore Ca<sup>2+</sup>/CaM‐dependent activation (Fink et al., <xref ref-type="ref" rid="humu23647-bib-0009">2003</xref>; Payne et al., <xref ref-type="ref" rid="humu23647-bib-0026">1988</xref>; Shen &amp; Meyer, <xref ref-type="ref" rid="humu23647-bib-0032">1999</xref>). In contrast, the CAMK2G<sup>Lys43Arg</sup> mutation impairs phosphotransferase activity (Fink et al., <xref ref-type="ref" rid="humu23647-bib-0009">2003</xref>; Shen &amp; Meyer, <xref ref-type="ref" rid="humu23647-bib-0032">1999</xref>). Notably, neither CAMK2G<sup>Ala303Arg</sup> nor CAMK2G<sup>Lys43Arg</sup> altered neurite length when expressed in cultured primary hippocampal neurons. Moreover, although a small but statistically significant increase of arborization was observed in CAMK2G<sup>Ala303Arg</sup> expressing neurons, no effect of arborization was found in neurons expressing CAMK2G<sup>Lys43Arg</sup> (Figure <xref ref-type="fig" rid="humu23647-fig-0003">3</xref>C and D). Finally, <italic>in vivo</italic> neural cell migration was also unaffected by expression of CAMK2G<sup>Ala303Arg</sup> or CAMK2G<sup>Lys43Arg</sup> (Figure <xref ref-type="fig" rid="humu23647-fig-0003">3</xref>E and F). Taken together these results show that expression of these phosphotransferase loss‐of‐function variants does not phenocopy the severe effects of the ID‐associated CAMK2G<sup>Arg292Pro</sup>, indicating that the CAMK2G<sup>Arg292Pro</sup> mutation is not a loss‐of‐function mutation.</p>
<p>We next tested the effect of the CAMK2G<sup>Thr287Asp/Thr306Val/Thr307Ala</sup> mutant, which has previously been shown to significantly enhance autonomous activity due to the combination of a Threonine 287 substitution by the phospho‐mimetic aspartic amino acid (Mayford, Wang, Kandel, &amp; O'Dell, <xref ref-type="ref" rid="humu23647-bib-0023">1995</xref>; Waldmann, Hanson, &amp; Schulman, <xref ref-type="ref" rid="humu23647-bib-0043">1990</xref>) together with prevention of inhibitory phosphorylation at the Thr306 and 307 sites by substituting conserved but non‐phosphorylatable amino acids (Elgersma et al., <xref ref-type="ref" rid="humu23647-bib-0008">2002</xref>; Pi et al., <xref ref-type="ref" rid="humu23647-bib-0027">2010a</xref>; Pi, Otmakhov, Lemelin, De Koninck, &amp; Lisman, <xref ref-type="ref" rid="humu23647-bib-0028">2010b</xref>). Interestingly, expression of this CAMK2G<sup>Thr287Asp/Thr306Val/Thr307Ala</sup> mutant in HEK‐293T cells also achieved severe reduction of CAMK2G protein signal compared to cells transfected with CAMK2G<sup>WT</sup> (data not shown). Consistent with the hypothesis that increased phosphotransferase activity is a critical mediator of the gain‐of‐function mechanism underlying the p.Arg292Pro mutation, expression of the CAMK2G<sup>Thr287Asp/Thr306Val/Thr307Ala</sup> mutant phenocopied CAMK2G<sup>Arg292Pro</sup> with similarly severe reductions of total neurite length (Figure <xref ref-type="fig" rid="humu23647-fig-0003">3</xref>C), arborization (Figure <xref ref-type="fig" rid="humu23647-fig-0003">3</xref>D), and neuronal migration (Figure <xref ref-type="fig" rid="humu23647-fig-0003">3</xref>E and F). These findings lend additional support to a model whereby the CAMK2G<sup>Arg292Pro</sup> mutation acts as a gain‐of‐function mutation by rendering CAMK2G constitutively active.</p>
</sec>
<sec id="humu23647-sec-0190">
<label>3.1.4</label>
<title>CAMK2G‐NLS<sup>Arg292Pro</sup> has impaired nuclear translocation while permitting calmodulin binding</title>
<p>Recently, it was shown that CAMK2G functions as a shuttle for Ca<sup>2+</sup>/CaM into the nucleus (Ma et al., <xref ref-type="ref" rid="humu23647-bib-0022">2014</xref>). Hence, we investigated if the p.Arg292Pro mutation impacts this shuttling function. Using the nuclear localization signal‐containing isoform of CAMK2G, we first confirmed the functional impact of CAMK2G‐NLS<sup>Arg292Pro</sup> on neuronal maturation and migration, which yielded the similarly severe neurodevelopmental impairments as CAMK2G<sup>Arg292Pro</sup> (<xref ref-type="supplementary-material" rid="humu23647-supl-0001">Suppl. Fig. S5</xref>). We then investigated whether CAMK2G‐NLS<sup>Arg292Pro</sup> affects CaM binding by performing a CaM immunoprecipitation. Despite reduced expression levels, we found that more CAMK2G‐NLS<sup>Arg292Pro</sup> is pulled down using the CaM antibody compared to CAMK2G‐NLS<sup>WT</sup> (Figure <xref ref-type="fig" rid="humu23647-fig-0004">4</xref>), suggesting that CaM binding is not disrupted, and even possibly that the affinity of CAMK2G‐NLS<sup>Arg292Pro</sup> for CaM is increased.</p>
<fig fig-type="Figure" id="humu23647-fig-0004" orientation="portrait" position="float" xml:lang="en">
<label>Figure 4</label>
<caption>
<p>The CAMK2G‐NLS<sup>Arg292Pro</sup> does not disrupt calmodulin binding. Representative western blot of a calmodulin immunoprecipitation experiment performed in HEK‐293T cells transfected with either control vector, CAMK2G‐NLS<sup>WT</sup>, CAMK2G‐NLS<sup>Arg292Pro</sup> (R292P), CAMK2G<sup>Ala303Arg</sup> (A303R), or non‐transfected (NT), probed with an antibody against CAMK2G, tdTOMATO, and calmodulin (CaM). Note the clear increase in CAMK2G pull‐down (in the presence of CaM antibody, left blot) in the mutant CAMK2G‐NLS<sup>Arg292Pro</sup> lane compared to the WT, despite the reduced stability of the mutant (as observed in the input). As expected, no detectable CAMK2G is observed in the CAMK2G<sup>Ala303Arg</sup> mutant lane. The “+” or “—” sign indicates the presence or absence, respectively of the calmodulin antibody</p>
</caption>
<graphic id="nlm-graphic-9" xlink:href="HUMU-39-2008-g004"></graphic>
</fig>
<p>Next, we assessed whether CAMK2G‐NLS<sup>Arg292Pro</sup> has impaired nuclear translocation. Neurons were transfected with CAMK2G‐NLS<sup>Arg292Pro</sup> and CAMK2G‐NLS<sup>WT</sup> to determine their respective subcellular localization. As expected, we found that CAMK2G‐NLS<sup>WT</sup> was located in the nucleus as well as the cytoplasm. In contrast, CAMK2G‐NLS<sup>Arg292Pro</sup> was almost exclusively localized to the cytoplasm (Figure <xref ref-type="fig" rid="humu23647-fig-0005">5</xref>A and B), suggesting that the p.Arg292Pro mutation disrupts the nuclear localization of CAMK2G‐NLS.</p>
<fig fig-type="Figure" id="humu23647-fig-0005" orientation="portrait" position="float" xml:lang="en">
<label>Figure 5</label>
<caption>
<p>The CAMK2G‐NLS<sup>Arg292Pro</sup> mutation interferes with nuclear translocation of CAMK2G‐NLS. (A and C) Representative confocal images of hippocampal (A) or cortical (C) neurons transfected on DIV7 with CAMK2G‐NLS<sup>WT</sup>, CAMK2G‐NLS<sup>Arg292Pro</sup> (R292P), CAMK2G‐NLS<sup>Ser334Ala</sup> (S224A), or CAMK2G‐NLS<sup>Arg292Pro/Ser334Ala</sup> (R292P/S334A). Transfected neurons are identified by the tdTOMATO (red). (B and D) Summary bar graphs of CAMK2G expression level measured as a ratio nucleus vs. cytoplasm and normalized to the WT level. (B: CAMK2G<sup>WT</sup> vs. CAMK2G<sup>Arg292Pro</sup>, <italic>P</italic> = 6.81E‐19, <italic>t</italic>(75) = 11.87, two‐tailed unpaired <italic>t</italic>‐test; D: one‐way ANOVA, <italic>F</italic>[3,86] = 43.58, <italic>P</italic> = 3.19E‐17; CAMK2G‐NLS<sup>WT</sup> vs. CAMK2G‐NLS<sup>Arg292Pro</sup>, <italic>P</italic> = 0.0001; CAMK2G‐NLS<sup>Ser334Ala</sup>, <italic>P</italic> = 0.99; CAMK2G‐NLS<sup>Arg292Pro/Ser334Ala</sup>, <italic>P</italic> = 0.0001; CAMK2G<sup>Arg292Pro</sup> vs. CAMK2G‐NLS<sup>Ser334Ala</sup>, <italic>P</italic> = 0.0001; CAMK2G‐NLS<sup>Arg292Pro/Ser334Ala</sup>, <italic>P</italic> = 0.99; CAMK2G‐NLS<sup>Ser334Ala</sup> vs. CAMK2G‐NLS<sup>Arg292Pro/Ser334Ala</sup>, <italic>P</italic> = 0.0001). Data are presented as mean ± SEM. Numbers (<italic>X</italic>/<italic>Y</italic>) depicted in the bar graphs represent the total number of cells (<italic>X</italic>) and number of independent cultures (<italic>Y</italic>) analyzed</p>
</caption>
<graphic id="nlm-graphic-11" xlink:href="HUMU-39-2008-g005"></graphic>
</fig>
<p>Nuclear translocation of NLS‐containing CAMK2 isoforms requires a conformational change previously been shown to be dependent upon dephosphorylation of a Serine immediately adjacent to the NLS sequence (Ser334 in CAMK2G), resulting in exposure of the NLS domain (Heist, Srinivasan, &amp; Schulman, <xref ref-type="ref" rid="humu23647-bib-0015">1998</xref>; Ma et al., <xref ref-type="ref" rid="humu23647-bib-0022">2014</xref>; Shioda, Sawai, Ishizuka, Shirao, &amp; Fukunaga, <xref ref-type="ref" rid="humu23647-bib-0033">2015</xref>). Given that the p.Arg292Pro mutation enhances the Serine/Threonine kinase activity of CAMK2G, we sought to investigate whether increased phosphorylation of the Ser334 residue is a critical mediator of the abnormal localization of CAMK2G‐NLS<sup>Arg292Pro</sup>. Therefore, we generated the CAMK2G‐NLS<sup>Ser334Ala</sup> mutant and the CAMK2G‐NLS<sup>Arg292Pro/Ser334Ala</sup> double mutant constructs to assess their respective subcellular localization. Whereas CAMK2G‐NLS<sup>Ser334Ala</sup> was localized in both the nucleus and the cytoplasm, CAMK2G‐NLS<sup>Arg292Pro/Ser334Ala</sup> remained exclusively cytoplasmic, indicating that the mislocalization resulting from the p.Arg292Pro mutation is not the result of excessive Ser334 phosphorylation (Figure <xref ref-type="fig" rid="humu23647-fig-0005">5</xref>C and D). Taken together, these data show that even though the p.Arg292Pro mutation does not reduce CaM affinity, it strongly impairs the nuclear localization of CAMK2G.</p>
</sec>
<sec id="humu23647-sec-0200">
<label>3.1.5</label>
<title>Pathogenicity of CAMK2G<sup>Arg292Pro</sup> is not related to nuclear shuttling of Ca<sup>2+</sup>/CaM</title>
<p>Our findings indicate that the p.Arg292Pro mutation has two major effects on CAMK2G: it renders the protein constitutively active and interferes with its nuclear targeting. Therefore, we next aimed to investigate whether the pathogenicity is caused by the constitutive activity or by the impairment of nuclear targeting.</p>
<p>To examine whether the constitutive activity results from the observed increase of Thr287 auto‐phosphorylation (Figure <xref ref-type="fig" rid="humu23647-fig-0003">3</xref>A and B), we mutated Threonine 287 to Alanine, a mutation that strongly reduces autonomous activity (Fong, Taylor, Means, &amp; Soderling, <xref ref-type="ref" rid="humu23647-bib-0010">1989</xref>; Giese et al., <xref ref-type="ref" rid="humu23647-bib-0011">1998</xref>; Hanson, Kapiloff, Lou, Rosenfeld, &amp; Schulman, <xref ref-type="ref" rid="humu23647-bib-0013">1989</xref>; Ohsako, Nakazawa, Sekihara, Ikai, &amp; Yamauchi, <xref ref-type="ref" rid="humu23647-bib-0024">1991</xref>; Waxham, Aronowski, Westgate, &amp; Kelly, <xref ref-type="ref" rid="humu23647-bib-0044">1990</xref>). Expression of CAMK2G<sup>Thr287Ala</sup> resulted in no discernible effects on morphology or neural cell migration (Figure <xref ref-type="fig" rid="humu23647-fig-0006">6</xref>). In contrast, expression of CAMK2G<sup>Thr287Ala/Arg292Pro</sup> was comparably disruptive as CAMK2G<sup>Arg292Pro</sup> on neuronal morphology and migration (Figure <xref ref-type="fig" rid="humu23647-fig-0006">6</xref>). These results indicate that functional consequences of the CAMK2G<sup>Arg292Pro</sup> mutation are independent of Thr287 phosphorylation.</p>
<fig fig-type="Figure" id="humu23647-fig-0006" orientation="portrait" position="float" xml:lang="en">
<label>Figure 6</label>
<caption>
<p>Auto‐phosphorylation at the Thr287 site is dispensable for the phenotype caused by the p.Arg292Pro mutation. (A) Representative confocal images of hippocampal neurons transfected on DIV7 with control vector, CAMK2G<sup>Arg292Pro</sup> (R292P), CAMK2G<sup>Thr287Ala</sup> (T287A), CAMK2G<sup>Thr287Ala/Arg292Pro</sup> (T287A/R292P). Transfected neurons are identified by the tdTOMATO (red). (B) Summary bar graphs of total neurite length and arborization measured for each condition and normalized to the control vector (total neurite length: one‐way ANOVA, <italic>F</italic>[3,70] = 69.33, <italic>P</italic> = 6.39E‐21; control vector vs. CAMK2G<sup>Arg292Pro</sup>, <italic>P</italic> = 0.0001; CAMK2G<sup>Thr287Ala</sup>, <italic>P</italic> = 0.9; CAMK2G<sup>Thr287Ala/Arg292Pro</sup>, <italic>P</italic> = 0.0001; CAMK2G<sup>Arg292Pro</sup> vs. CAMK2G<sup>Thr287Ala</sup>, <italic>P</italic> = 0.0001; CAMK2G<sup>Thr287Ala/Arg292Pro</sup>, <italic>P</italic> = 0.99; CAMK2G<sup>Thr287Ala</sup> vs. CAMK2G<sup>Thr287Ala/Arg292Pro</sup>, <italic>P</italic> = 0.0001; arborization: one‐way ANOVA, <italic>F</italic>[3,71] = 34.88, <italic>P</italic> = 5.74E‐14; control vector vs. CAMK2G<sup>Arg292Pro</sup>, <italic>P</italic> = 0.0001; CAMK2G<sup>Thr287Ala</sup>, <italic>P</italic> = 0.9; CAMK2G<sup>Thr287Ala/Arg292Pro</sup>, <italic>P</italic> = 0.0001; CAMK2G<sup>Arg292Pro</sup> vs. CAMK2G<sup>Thr287Ala</sup>, <italic>P</italic> = 0.0001; CAMK2G<sup>T287A/R292P</sup>, <italic>P</italic> = 0.99; CAMK2G<sup>Thr287Ala</sup> vs. CAMK2G<sup>Thr287Ala/Arg292Pro</sup>, <italic>P</italic> = 0.0001). (C) Representative image of a P20 pup <italic>in utero</italic> electroporated at E14.5 with CAMK2G<sup>Thr287Ala</sup> or CAMK2G<sup>Thr287Ala/Arg292Pro</sup>. tdTOMATO positive cells represent neurons successfully targeted. DAPI (blue) counterstaining is used to identify general cortical structure. (D) Upper graph: quantification of the neuronal migration pattern from the Layer 1 (L1) to the intermediate zone (IZ); Lower graph: analysis of the percentage of targeted cells that reach the outer layers of the cortex measured as sum of bin 1–4 (one‐way ANOVA, <italic>F</italic>[2,16] = 24.34, <italic>P</italic> = 1.40E‐05; CAMK2G<sup>WT</sup> vs. CAMK2G<sup>Thr287Ala</sup>, <italic>P</italic> = 0.99; CAMK2G<sup>Thr287Ala/Arg292Pro</sup>, <italic>P</italic> = 0.0001; CAMK2G<sup>Thr287Ala</sup> vs. CAMK2G<sup>Thr287Ala/Arg292Pro</sup>, <italic>P</italic> = 0.0001). The dotted line represents the level reached by the CAMK2G‐WT (see Figure <xref ref-type="fig" rid="humu23647-fig-0002">2</xref>F for comparison). Arrowheads indicate layer 2/3 of the somatosensory cortex, whereas the arrow indicates the subventricular zone (SVZ). Data in (B) and (D) are presented as mean ± SEM. Numbers (<italic>X</italic>/<italic>Y</italic>) depicted in the bar graphs represent the total number of cells (<italic>X</italic>) and number of independent cultures (<italic>Y</italic>) (B) or number of pictures (D) analyzed</p>
</caption>
<graphic id="nlm-graphic-13" xlink:href="HUMU-39-2008-g006"></graphic>
</fig>
<p>We next examined whether the p.Arg292Pro mutation gain‐of‐function requires the catalytic function of the kinase by introducing a p.Lys43Arg mutation, known to severely disable CAMK2G catalytic function. Compared to the severe neurodevelopmental impairments resulting from expression of CAMK2G<sup>Arg292Pro</sup>, CAMK2G<sup>Arg292Pro/Lys43Arg</sup> had a significantly milder impact on total neurite length and fully rescued arborization (Figure <xref ref-type="fig" rid="humu23647-fig-0007">7</xref>A). Moreover, CAMK2G<sup>Arg292Pro/Lys43Arg</sup> expressing cells targeted at E14.5 by <italic>in utero</italic> electroporation revealed no discernible migration deficits compared to CAMK2G<sup>WT</sup> (Figure <xref ref-type="fig" rid="humu23647-fig-0002">2</xref>F, Figure <xref ref-type="fig" rid="humu23647-fig-0007">7</xref>C and D), indicating that the pathogenicity of CAMK2G<sup>Arg292Pro</sup> requires its kinase activity.</p>
<fig fig-type="Figure" id="humu23647-fig-0007" orientation="portrait" position="float" xml:lang="en">
<label>Figure 7</label>
<caption>
<p>Silencing the catalytic activity of CAMK2G<sup>Arg292Pro</sup> normalizes neuronal maturation and migration. (A) Representative confocal images of hippocampal neurons transfected on DIV7 with control vector or CAMK2G<sup>Lys43Arg/Arg292Pro</sup> (K43R/R292P). Transfected neurons are identified by the tdTOMATO (red). (B) Summary bar graphs of total neurite length and arborization measured for each condition and normalized to the control vector (total neurite length: one‐way ANOVA, <italic>F</italic>[2,61] = 18.50, <italic>P</italic> = 5.25E‐07; CAMK2G<sup>Lys43Arg/Arg292Pro</sup> vs. control vector: <italic>P</italic> = 0.05; CAMK2G<sup>Arg292Pro</sup>: <italic>P</italic> = 0.01; arborization: one‐way ANOVA, <italic>F</italic>[2,61] = 15.02, <italic>P</italic> = 4.97E‐06; CAMK2G<sup>Lys43Arg/Arg292Pro</sup> vs. control vector, <italic>P</italic> = 0.16; CAMK2G<sup>Arg292Pro</sup>, <italic>P</italic> = 0.01). (C) Representative image of a P20 pup <italic>in utero</italic> electroporated at E14.5 with CAMK2G<sup>Lys43Arg/Arg292Pro</sup>. tdTOMATO positive cells represent neurons successfully targeted. DAPI (blue) counterstaining is used to identify general cortical structure. (D) Left: quantification of the neuronal migration pattern from the Layer 1 (L1) to the intermediate zone (IZ); Right: analysis of the percentage of targeted cells that reach the outer layers of the cortex measured as the sum of bin 1–4 (CAMK2G<sup>WT</sup> vs. CAMK2G<sup>Lys43Arg/Arg292Pro</sup>, <italic>t</italic>[15] = 0.83, <italic>P</italic> = 0.42, two‐tailed unpaired <italic>t</italic>‐test).The dotted line indicates the CAMK2G<sup>WT</sup> level, see Figure <xref ref-type="fig" rid="humu23647-fig-0002">2</xref>F for comparison. Arrowheads indicate layer 2/3 of the somatosensory cortex, whereas the arrow indicates the subventricular zone (SVZ). Data in (B) and (D) are presented as mean±SEM. Numbers (<italic>X</italic>/<italic>Y</italic>) depicted in the bar graphs represent the total number of cells (<italic>X</italic>) and number of independent cultures (<italic>Y</italic>) (B) or number of pictures (D) analyzed</p>
</caption>
<graphic id="nlm-graphic-15" xlink:href="HUMU-39-2008-g007"></graphic>
</fig>
<p>Since the introduction of the p.Lys43Arg mutation into the exclusively cytosolic CAMK2G<sup>Arg292Pro</sup> isoform strongly attenuates the pathogenicity of the Arg292Pro mutation, we hypothesized that the pathogenicity of the p.Arg292Pro mutation is independent of its function as a nuclear Ca/CaM shuttle. To investigate this, we introduced the p.Lys43Arg mutation into the CAMK2G that carries an NLS, resulting in CAMK2G‐NLS<sup>Arg292Pro</sup>. Analysis of the CAMK2G‐NLS<sup>Lys43Arg/Arg292Pro</sup> double mutation showed that the Lys43Arg mutation did not alter the nuclear targeting deficit (<xref ref-type="supplementary-material" rid="humu23647-supl-0001">Suppl. Fig. S6</xref>A and B). Nevertheless, both neuronal maturation and migration were again fully rescued by introducing the p.Lys43Arg mutation (<xref ref-type="supplementary-material" rid="humu23647-supl-0001">Suppl. Fig. S6</xref>C–E).</p>
<p>Taken together these experiments suggest that the p.Arg292Pro mutation renders CAMK2G constitutively active and impairs neuronal maturation and migration independent of its role as a Ca<sup>2+</sup>/CaM shuttle.</p>
</sec>
<sec id="humu23647-sec-0210">
<label>3.1.6</label>
<title>The CAMK2G<sup>Arg292Pro</sup> analogous mutations in CAMK2A and CAMK2B exhibit similar neurodevelopmental pathogenicity as CAMK2G<sup>Arg292Pro</sup>
</title>
<p>Given that CAMK2G<sup>Arg292Pro</sup> exerts the pathogenic phenotype we describe via a non‐nuclear function, we hypothesized that the analogous mutations in CAMK2A or CAMK2B lacking an NLS might be similarly disruptive for neurodevelopment, given that they are almost exclusively localized to the cytoplasm. Therefore, we generated the analogous mutations of CAMK2G<sup>Arg292Pro</sup> in CAMK2A and CAMK2B (Figure <xref ref-type="fig" rid="humu23647-fig-0008">8</xref>A). We first investigated the basal Thr286 and Thr287 phosphorylation levels of CAMK2A and CAMK2B, respectively. Whereas basal auto‐phosphorylation in HEK‐293T cells of CAMK2G<sup>WT</sup> was clearly evident, that of CAMK2A<sup>WT</sup> or CAMK2B<sup>WT</sup> was hardly detectible (Figure <xref ref-type="fig" rid="humu23647-fig-0008">8</xref>B). In contrast, both CAMK2A<sup>Lys291Pro</sup> and CAMK2B<sup>Lys292Pro</sup> exhibited robust basal Thr286/287 phosphorylation (Figure <xref ref-type="fig" rid="humu23647-fig-0008">8</xref>C), indicating that this Arg/Lys residue functions critically across multiple CAMK2 isoforms for constraining phosphotransferase activity.</p>
<fig fig-type="Figure" id="humu23647-fig-0008" orientation="portrait" position="float" xml:lang="en">
<label>Figure 8</label>
<caption>
<p>CAMK2A<sup>Lys291Pro</sup> and CAMK2B<sup>Lys292Pro</sup> exhibit similar neurodevelopmental pathogenicity as CAMK2G<sup>Arg292Pro</sup>. (A) Alignment of the protein sequence of CAMK2A, CAMK2B, and CAMK2G showing that the Arginine (R) at 292 in CAMK2G is a Lysine (K) in CAMK2A and CAMK2B. (B) Representative western blot of HEK‐293T cells transfected with control vector, CAMK2A<sup>WT</sup>, CAMK2A<sup>Lys291Pro</sup> (K291P), CAMK2B<sup>WT</sup>, or CAMK2B<sup>Lys292Pro</sup> (K292P). (C) Quantification of the levels of CAMK2–Thr286/Thr287 phosphorylation, normalized against total CAMK2 in the different conditions (CAMK2A<sup>WT</sup> vs. CAMK2A<sup>Lys291Pro</sup>, <italic>t</italic>[12] = 2.7, <italic>P</italic> = 0.01; CAMK2B<sup>WT</sup> vs. CAMK2B<sup>Lys292Pro</sup>, <italic>t</italic>(8) = 2.18, <italic>P</italic> = 0.03, one‐tailed unpaired <italic>t</italic>‐test). (D) Representative confocal images of hippocampal neurons transfected on DIV7 with control vector, CAMK2A<sup>WT</sup>, CAMK2A<sup>Lys291Pro</sup>, CAMK2B<sup>WT</sup>, or CAMK2B<sup>Lys292Pro</sup>. Transfected neurons are identified by the tdTOMATO (red). (E) Summary bar graphs of total neurite length and arborization measured for each condition and normalized to the control vector (CAMK2A total neurite length: one‐way ANOVA, <italic>F</italic>[2,56] = 3.38, <italic>P</italic> = 0.04; control vector vs. CAMK2A<sup>WT</sup>, <italic>P</italic> = 0.9; CAMK2A<sup>Lys291Pro</sup>, <italic>P</italic> = 0.1, CAMK2A<sup>WT</sup> vs. CAMK2A<sup>Lys291Pro</sup>, <italic>P</italic> = 0.06; CAMK2A arborization: one‐way ANOVA <italic>F</italic>[2,56] = 6.37, <italic>P</italic> = 0.003; control vector vs. CAMK2A<sup>WT</sup>, <italic>P</italic> = 0.6; CAMK2A<sup>Lys291Pro</sup>, <italic>P</italic> = 0.04, CAMK2A<sup>WT</sup> vs. CAMK2A<sup>Lys291Pro</sup>, <italic>P</italic> = 0.003; CAMK2B total neurite length: one‐way ANOVA, <italic>F</italic>[2,55] = 27.26, <italic>P</italic> = 5,9E‐09; control vector vs. CAMK2B<sup>WT</sup>, <italic>P</italic> = 0.5; CAMK2B<sup>Lys292Pro</sup>, <italic>P</italic> = 0.0001, CAMK2B<sup>WT</sup> vs. CAMK2B<sup>Lys292Pro</sup>, <italic>P</italic> = 0.0001; CAMK2B arborization: one‐way ANOVA <italic>F</italic>[2,55] = 29.07, <italic>P</italic> = 2.4E‐09; control vector vs. CAMK2B<sup>WT</sup>, <italic>P</italic> = 0.02; CAMK2B<sup>Lys292Pro</sup>, <italic>P</italic> = 0.0001, CAMK2B<sup>WT</sup> vs. CAMK2B<sup>Lys292Pro</sup>, <italic>P</italic> = 0.0001). (F) Representative images of P20–P22 pups <italic>in utero</italic> electroporated at E14.5 with control vector, CAMK2A<sup>WT</sup>, CAMK2A<sup>Lys291Pro</sup>, CAMK2B<sup>WT</sup>, or CAMK2B<sup>Lys292Pro</sup>. tdTOMATO positive cells represent neurons successfully targeted. Arrowheads indicate layer 2/3 of the somatosensory cortex, whereas the arrowhead indicates the subventricular zone (SVZ). Right: quantification of the neuronal migration pattern from the Layer 1 (L1) to the intermediate zone (IZ); insets represent the percentage of targeted cells that reach the outer layers of the cortex measured as the sum of bin 1–4 (CAMK2A<sup>WT</sup> vs. CAMK2A<sup>Lys291Pro</sup>, <italic>t</italic>(29) = 12.97, <italic>P</italic> = 1.34E‐13, unpaired two‐tailed <italic>t</italic>‐test; CAMK2B<sup>WT</sup> vs. CAMK2B<sup>Lys292Pro</sup>, <italic>t</italic>(23) = 13.33, <italic>P</italic> = 2.64E‐12, unpaired two‐tailed <italic>t</italic>‐test). Data in (C) and (E) are presented as mean ± SEM. Numbers (<italic>X</italic>/<italic>Y</italic>) depicted in the bar graphs represent the number of samples (C) or the total number of cells (<italic>X</italic>) and number of independent cultures (<italic>Y</italic>) (E) analyzed</p>
</caption>
<graphic id="nlm-graphic-17" xlink:href="HUMU-39-2008-g008"></graphic>
</fig>
<p>We next tested whether the expression of CAMK2A<sup>Lys291Pro</sup> and CAMK2B<sup>Lys292Pro</sup> impacts the morphological development of cultured primary hippocampal neurons (Figure <xref ref-type="fig" rid="humu23647-fig-0008">8</xref>D). No changes in neuronal morphology were observed with expression of CAMK2A<sup>WT</sup> (Figure <xref ref-type="fig" rid="humu23647-fig-0008">8</xref>E). Expression of CAMK2B<sup>WT</sup> did result in a small but significant decrease in arborization, but without changes in total neurite length (Figure <xref ref-type="fig" rid="humu23647-fig-0008">8</xref>E). In contrast, expression of either CAMK2A<sup>Lys291Pro</sup> or CAMK2B<sup>Lys292Pro</sup> each resulted in substantial alterations of neuronal morphology (Figure <xref ref-type="fig" rid="humu23647-fig-0008">8</xref>D and E).</p>
<p>Lastly, we evaluated the impact of CAMK2A<sup>Lys291Pro</sup> and CAMK2B<sup>Lys292Pro</sup> on <italic>in vivo</italic> neural cell migration. The majority of cells expressing either CAMK2A<sup>WT</sup> or CAMK2B<sup>WT</sup> migrated normally to layer 2/3 of the somatosensory cortex (Figure <xref ref-type="fig" rid="humu23647-fig-0008">8</xref>F). However, expression of either CAMK2A<sup>Lys291Pro</sup> or CAMK2B<sup>Lys292Pro</sup> caused a severe disruption of migration, analogous to the effect of CAMK2G<sup>Arg292Pro</sup> (Figure <xref ref-type="fig" rid="humu23647-fig-0008">8</xref>F).</p>
<p>Therefore, our findings suggest a strong functional conservation across the major brain‐expressed CAMK2 isoforms of the ID‐associated CAMK2G p.Arg292Pro mutation for which neurodevelopmental pathogenicity is mediated by a gain‐of‐function through enhanced cytoplasmic phosphotransferase activity.</p>
</sec>
</sec>
</sec>
<sec id="humu23647-sec-0220">
<label>4</label>
<title>DISCUSSION</title>
<p>In the present study, we describe two unrelated patients with severe ID, carrying a <italic>de novo</italic> CAMK2G p.Arg292Pro mutation and made use of an <italic>in vitro</italic> morphology and <italic>in vivo</italic> migration assay to investigate the pathogenicity of this mutation.</p>
<p>Mutations in <italic>CAMK2A</italic> and <italic>CAMK2B</italic> have recently been shown to cause ID, severely delayed speech and behavioral issues (Küry et al., <xref ref-type="ref" rid="humu23647-bib-0018">2017</xref>). Apart from these common features, there is much variability between the different CAMK2 patients. The two patients described here carrying a mutation in CAMK2G share similar features with <italic>CAMK2A</italic>/<italic>CAMK2B</italic>‐mutated patients (e.g., ID and hypotonia), but also show clear differences such as facial dysmorphisms. The continuous identification of individuals with ID carrying mutations in the CAMK2 genes, may enable further characterization of specific characteristics for the CAMK2‐dependent syndrome.</p>
<p>We have established several lines of mechanistic evidence indicating that the p.Arg292Pro mutation acts as a gain‐of‐function, with regard to catalytic activity of the kinase, but as a loss‐of‐function with regard to its nuclear localization. First, we showed that expression of CAMK2G mutants that reduce kinase activity by interfering with Ca<sup>2+</sup>/CaM binding or rendering the protein kinase‐dead, do not recapitulate the neurodevelopmental phenotypes exhibited by expression of CAMK2G<sup>Arg292Pro</sup>. Second, we showed that the CAMK2G p.Arg292Pro mutation causes increased phosphotransferase activity as well as increased CaM affinity, resulting in increased Thr287 phosphorylation. Third, we showed that expression of the constitutively active mutant CAMK2G<sup>Thr287Asp/Thr306Val/Thr307Ala</sup> phenocopies the neurodevelopmental impairments seen with expression of CAMK2G<sup>Arg292Pro</sup>. Finally, we showed that CAMK2G‐NLS<sup>Arg292Pro</sup> is deficient in nuclear localization. Taken together, we propose a model whereby the p.Arg292Pro mutation renders CAMK2G constitutively active albeit with a reduced protein half‐life, either due to intrinsic instability or targeted degradation. Notably, expression of the constitutively active CAMK2G<sup>Thr287Asp/Thr306Val/Thr307Ala</sup> mutant in HEK‐293T cells also resulted in lower CAMK2G protein expression but the higher activity of the expressed protein led to the gain‐of‐function phenotype. Additionally, mice expressing the CAMK2A<sup>Thr305Val/Thr306Ala</sup> protein, which lacks auto‐inhibitory function, exhibits a two‐fold reduction in CAMK2A protein but similarly produces a net gain‐of‐function phenotype (Elgersma et al., <xref ref-type="ref" rid="humu23647-bib-0008">2002</xref>). Since CAMK2 is highly dependent on a Ca<sup>2+</sup> stimulus for activity, even low expression of a constitutively active form such as CAMK2G<sup>Arg292Pro</sup> may elicit gain‐of‐function effects. Future studies using a targeted mouse mutant and genome‐edited human pluripotent stem cells would provide further insights regarding the endogenous regulation of CAMK2G<sup>Arg292Pro</sup> protein levels.</p>
<p>Although the effect of the CAMK2G<sup>Arg292Pro</sup> mutation has not previously been studied, our finding that its pathogenicity derives from a gain‐of‐function is consistent with the rich knowledge of CAMK2 biochemistry (for reviews see, Hudmon and Schulman (<xref ref-type="ref" rid="humu23647-bib-0017">2002</xref>); Lisman et al. (<xref ref-type="ref" rid="humu23647-bib-0020">2002</xref>)). In the basal state, the auto‐regulatory domain functions to suppress catalytic activity by maintaining the kinase in an inactive conformation and blocking access of external substrates to the binding pocket. Binding of Ca<sup>2+</sup>/CaM to the auto‐regulatory domain displaces it to allow the active conformation and opening the substrate binding pocket. In the process, it exposes Thr286 (CAMK2A)/Thr287 (CAMK2B and CAMK2G) for auto‐phosphorylation, which disables the inhibitory function of the auto‐regulatory domain and results in Ca<sup>2+</sup>/CaM independent (autonomous) activity. The auto‐regulatory domain consists of several residues that participate in auto‐inhibition, one of which is located at amino acid position 291 in CAMK2A (Smith, Colbran, Brickey, &amp; Soderling, <xref ref-type="ref" rid="humu23647-bib-0036">1992</xref>). Indeed, for CAMK2A it has previously been shown that mutation of Lysine 291 (equivalent to Arginine 292 in CAMK2G) to Alanine increases the K<sub>i</sub> for inhibitory peptides and reduced the inhibitory potency of the auto‐regulatory domain (Smith et al., <xref ref-type="ref" rid="humu23647-bib-0036">1992</xref>). Notably, mutation of CAMK2A just three residues downstream, from Asparagine 294 to aspartic acid, generates an even greater enhancement of constitutive activity than the phosphomimetic p.Thr286Asp mutation. Therefore, it is possible that the disruptive nature of the Proline substitution in p.Arg292Pro reduces the contribution of the critical Asparagine for auto‐inhibition resulting in enhanced constitutive activity (Yang &amp; Schulman, <xref ref-type="ref" rid="humu23647-bib-0045">1999</xref>). Additionally, mutation of CAMK2A Lysine 291 to Glutamic acid reduced the relative K<sub>CaM</sub> by 50%, thereby increasing CaM binding (Yang &amp; Schulman, <xref ref-type="ref" rid="humu23647-bib-0045">1999</xref>). Hence, these structural and biochemical findings are entirely consistent with our finding that the p.Arg292Pro mutation would generates a constitutively active kinase that facilitates CaM binding and promotes Thr287 phosphorylation that delinks kinase activity from complete dependence on Ca<sup>2+</sup> stimulus for activity.</p>
<p>Our finding that knockdown of CAMK2G affects neuronal arborization, which could be rescued by CAMK2G expression with or without an NLS, but not by heterologous CAMK2A or CAMK2B overexpression indicates that cytosolic CAMK2G plays a unique role in neuronal development, and that loss‐of‐function mutations or haploinsufficiency could potentially be disruptive. Indeed, according to ExAC, the probability of CAMK2G being LoF intolerant is high (pLI = 0.99). However, to our knowledge no patient with a neurodevelopmental disorder has yet been found carrying an indel or a nonsense mutation in the <italic>CAMK2G</italic> gene. Interestingly, another CAMK2G candidate variant (CAMK2G c.1075G &gt; A p.Val359Met) was found in a patient with a developmental disorder in the Deciphering Developmental Disorders Study (Deciphering Developmental Disorders Study, <xref ref-type="ref" rid="humu23647-bib-0007">2017</xref>). In contrast to the p.Arg292Pro mutation, this variant is located in the association domain of the protein, which makes it difficult to predict <italic>a priori</italic> if and how it affects CAMK2G protein function.</p>
<p>Very few studies have looked at the function of CAMK2G in neurons. Only recently, a first hint for CAMK2G having a unique function in spinal cord ganglion cells was published (Ma et al., <xref ref-type="ref" rid="humu23647-bib-0022">2014</xref>). This study indicated that CAMK2G functions as a shuttle to transport Ca<sup>2+</sup>/CaM from the cell surface and cytoplasm to the nucleus, a function that does not require its catalytic activity but depends on phosphorylation of its Thr287 by a second CAMK2 holoenzyme, and on the integrity of its NLS to initiate changes in gene expression in response to specific Ca<sup>2+</sup> signals. Our study further expands the mechanistic evidence underlying the function of CAMK2G in neurons by demonstrating that reduced levels of CAMK2G resulted in a significant elaboration of neuronal morphology. Notably, this effect could be reversed by expression of CAMK2G with or without an NLS, but not by expression of CAMK2A or CAMK2B. Therefore, we conclude that cytosolic CAMK2G functions to constrain dendritic arborization. In contrast, whereas CAMK2A knockdown does not affect dendritic arborization, CAMK2B knockdown has been shown to reduce dendritic arborization of primary hippocampal neurons (Fink et al., <xref ref-type="ref" rid="humu23647-bib-0009">2003</xref>), together suggesting distinct neurodevelopmental functions of the various CAMK2 isoforms.</p>
<p>Even though a subset of CAMK2G isoforms contains an NLS (Takeuchi, Fukunaga, &amp; Miyamoto, <xref ref-type="ref" rid="humu23647-bib-0038">2002</xref>), we did not observe differential effects on neuronal morphology or neural cell migration that were dependent on the presence of the NLS domain. However, we did find that CAMK2G‐NLS<sup>Arg292Pro</sup> is localized predominantly to the cytosol, whereas CAMK2G‐NLS<sup>WT</sup> is located in both the nucleus and cytosol, indicating that the p.Arg292Pro mutation interferes with its nuclear localization. However, given that abrogation of the phosphotransferase activity (via the Lys43Arg mutation) fully rescued the pathogenic effect of the p.Arg292Pro mutation, independently of the presence or absence of the NLS domain, we conclude that the pathogenicity of the p.Arg292Pro mutation is most likely unrelated to its nuclear function.</p>
<p>Our results also demonstrate that the combination of <italic>in vitro</italic> and <italic>in vivo</italic> neurodevelopmental assays provide a robust platform for investigating the functional pathogenicity of candidate CAMK2 mutations for ID. Furthermore, by exploiting the wealth of previous data that has been gathered for the CAMK2 protein (Colbran, <xref ref-type="ref" rid="humu23647-bib-0003">1992</xref>; Colbran &amp; Brown, <xref ref-type="ref" rid="humu23647-bib-0004">2004</xref>; Hanson, Meyer, Stryer, &amp; Schulman, <xref ref-type="ref" rid="humu23647-bib-0014">1994</xref>; Hudmon &amp; Schulman, <xref ref-type="ref" rid="humu23647-bib-0017">2002</xref>; Rellos et al., <xref ref-type="ref" rid="humu23647-bib-0029">2010</xref>; Yang &amp; Schulman, <xref ref-type="ref" rid="humu23647-bib-0045">1999</xref>), we were subsequently able to carefully dissect the biochemical mechanism underlying the pathogenicity of the mutation.</p>
<p>In conclusion, we show that CAMK2G is indispensable for normally developing neurons. Moreover, we have demonstrated that the pathogenicity of the <italic>de novo</italic> CAMK2G p.Arg292Pro mutation is mediated by a gain‐of‐function through enhanced constitutive enzymatic activity.</p>
</sec>
<sec id="humu23647-sec-0240">
<title>CONFLICT OF INTEREST STATEMENT</title>
<p>The Greenwood Genetic Center receives fee income from clinical laboratory testing.</p>
</sec>
<sec sec-type="supplementary-material">
<title>Supporting information</title>
<supplementary-material content-type="local-data" id="humu23647-supl-0001">
<caption>
<p>Supporting information</p>
</caption>
<media xlink:href="HUMU-39-2008-s001.docx">
<caption>
<p>Click here for additional data file.</p>
</caption>
</media>
</supplementary-material>
</sec>
</body>
<back>
<ack id="humu23647-sec-0230">
<title>ACKNOWLEDGMENTS</title>
<p>We thank Erika Goedknegt, Minetta Elgersma, Mehrnoush Aghadavoud Jolfaei, Christian G. Bouwkamp, Charlotte de Konink, and Randall de Joode for technical support.</p>
</ack>
<ref-list id="humu23647-bibl-0001">
<title>REFERENCES</title>
<ref id="humu23647-bib-0001">
<mixed-citation id="humu23647-cit-0001" publication-type="journal">
<string-name>
<surname>Bayer</surname>, <given-names>K. U.</given-names>
</string-name>, <string-name>
<surname>Löhler</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Schulman</surname>, <given-names>H.</given-names>
</string-name>, &amp; <string-name>
<surname>Harbers</surname>, <given-names>K.</given-names>
</string-name> (<year>1999</year>). <article-title>Developmental expression of the CaM kinase II isoforms: Ubiquitous gamma‐ and delta‐CaM kinase II are the early isoforms and most abundant in the developing nervous system</article-title>. <source xml:lang="en"/>Brain Research. Molecular Brain Research, <volume>70</volume>(<issue>1</issue>), <fpage>147</fpage>–<lpage>154</lpage>.<pub-id pub-id-type="pmid">10381553</pub-id></mixed-citation>
</ref>
<ref id="humu23647-bib-0002">
<mixed-citation id="humu23647-cit-0002" publication-type="journal">
<string-name>
<surname>Borgesius</surname>, <given-names>N. Z.</given-names>
</string-name>, <string-name>
<surname>van Woerden</surname>, <given-names>G. M.</given-names>
</string-name>, <string-name>
<surname>Buitendijk</surname>, <given-names>G. H. S.</given-names>
</string-name>, <string-name>
<surname>Keijzer</surname>, <given-names>N.</given-names>
</string-name>, <string-name>
<surname>Jaarsma</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Hoogenraad</surname>, <given-names>C. C.</given-names>
</string-name>, &amp; <string-name>
<surname>Elgersma</surname>, <given-names>Y.</given-names>
</string-name> (<year>2011</year>). <article-title>βCaMKII plays a nonenzymatic role in hippocampal synaptic plasticity and learning by targeting αCaMKII to synapses</article-title>. <source xml:lang="en"/>The Journal of Neuroscience: The Official Journal of the Society for Neuroscience, <volume>31</volume>(<issue>28</issue>), <fpage>10141</fpage>–<lpage>10148</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.5105-10.2011</pub-id>
<pub-id pub-id-type="pmid">21752990</pub-id></mixed-citation>
</ref>
<ref id="humu23647-bib-0003">
<mixed-citation id="humu23647-cit-0003" publication-type="journal">
<string-name>
<surname>Colbran</surname>, <given-names>R. J.</given-names>
</string-name> (<year>1992</year>). <article-title>Regulation and role of brain calcium/calmodulin‐dependent protein kinase II</article-title>. <source xml:lang="en"/>Neurochemistry International, <volume>21</volume>(<issue>4</issue>), <fpage>469</fpage>–<lpage>497</lpage>.<pub-id pub-id-type="pmid">1338943</pub-id></mixed-citation>
</ref>
<ref id="humu23647-bib-0004">
<mixed-citation id="humu23647-cit-0004" publication-type="journal">
<string-name>
<surname>Colbran</surname>, <given-names>R. J.</given-names>
</string-name>, &amp; <string-name>
<surname>Brown</surname>, <given-names>A. M.</given-names>
</string-name> (<year>2004</year>). <article-title>Calcium/calmodulin‐dependent protein kinase II and synaptic plasticity</article-title>. <source xml:lang="en"/>Current Opinion in Neurobiology, <volume>14</volume>(<issue>3</issue>), <fpage>318</fpage>–<lpage>327</lpage>. <pub-id pub-id-type="doi">10.1016/j.conb.2004.05.008</pub-id>
<pub-id pub-id-type="pmid">15194112</pub-id></mixed-citation>
</ref>
<ref id="humu23647-bib-0005">
<mixed-citation id="humu23647-cit-0005" publication-type="journal">
<string-name>
<surname>de Ligt</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Willemsen</surname>, <given-names>M. H.</given-names>
</string-name>, <string-name>
<surname>van Bon</surname>, <given-names>B. W. M.</given-names>
</string-name>, <string-name>
<surname>Kleefstra</surname>, <given-names>T.</given-names>
</string-name>, <string-name>
<surname>Yntema</surname>, <given-names>H. G.</given-names>
</string-name>, … <string-name>
<surname>Kroes</surname>, <given-names>T.</given-names>
</string-name> (<year>2012</year>). <article-title>Diagnostic exome sequencing in persons with severe intellectual disability</article-title>. <source xml:lang="en"/>The New England Journal of Medicine, <volume>367</volume>(<issue>20</issue>), <fpage>1921</fpage>–<lpage>1929</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa1206524</pub-id>
<pub-id pub-id-type="pmid">23033978</pub-id></mixed-citation>
</ref>
<ref id="humu23647-bib-0006">
<mixed-citation id="humu23647-cit-0006" publication-type="journal">
<string-name>
<surname>de Quervain</surname>, <given-names>D. J.‐F.</given-names>
</string-name>, &amp; <string-name>
<surname>Papassotiropoulos</surname>, <given-names>A.</given-names>
</string-name> (<year>2006</year>). <article-title>Identification of a genetic cluster influencing memory performance and hippocampal activity in humans</article-title>. <source xml:lang="en"/>Proceedings of the National Academy of Sciences of the United States of America, <volume>103</volume>(<issue>11</issue>), <fpage>4270</fpage>–<lpage>4274</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0510212103</pub-id>
<pub-id pub-id-type="pmid">16537520</pub-id></mixed-citation>
</ref>
<ref id="humu23647-bib-0007">
<mixed-citation id="humu23647-cit-0007" publication-type="journal">
<collab collab-type="authors">Deciphering Developmental Disorders Study</collab>
. (<year>2017</year>). <article-title>Prevalence and architecture of de novo mutations in developmental disorders</article-title>. <source xml:lang="en"/>Nature, <volume>542</volume>(<issue>7642</issue>), <fpage>433</fpage>–<lpage>438</lpage>. <pub-id pub-id-type="doi">10.1038/nature21062</pub-id>
<pub-id pub-id-type="pmid">28135719</pub-id></mixed-citation>
</ref>
<ref id="humu23647-bib-0008">
<mixed-citation id="humu23647-cit-0008" publication-type="journal">
<string-name>
<surname>Elgersma</surname>, <given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Fedorov</surname>, <given-names>N. B.</given-names>
</string-name>, <string-name>
<surname>Ikonen</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Choi</surname>, <given-names>E. S.</given-names>
</string-name>, <string-name>
<surname>Elgersma</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Carvalho</surname>, <given-names>O. M.</given-names>
</string-name>, … <string-name>
<surname>Silva</surname>, <given-names>A. J.</given-names>
</string-name> (<year>2002</year>). <article-title>Inhibitory autophosphorylation of CaMKII controls PSD association, plasticity, and learning</article-title>. <source xml:lang="en"/>Neuron, <volume>36</volume>(<issue>3</issue>), <fpage>493</fpage>–<lpage>505</lpage>.<pub-id pub-id-type="pmid">12408851</pub-id></mixed-citation>
</ref>
<ref id="humu23647-bib-0009">
<mixed-citation id="humu23647-cit-0009" publication-type="journal">
<string-name>
<surname>Fink</surname>, <given-names>C. C.</given-names>
</string-name>, <string-name>
<surname>Bayer</surname>, <given-names>K.‐U.</given-names>
</string-name>, <string-name>
<surname>Myers</surname>, <given-names>J. W.</given-names>
</string-name>, <string-name>
<surname>Ferrell</surname>, <given-names>J. E.</given-names>
</string-name>, <string-name>
<surname>Schulman</surname>, <given-names>H.</given-names>
</string-name>, &amp; <string-name>
<surname>Meyer</surname>, <given-names>T.</given-names>
</string-name> (<year>2003</year>). <article-title>Selective regulation of neurite extension and synapse formation by the beta but not the alpha isoform of CaMKII</article-title>. <source xml:lang="en"/>Neuron, <volume>39</volume>(<issue>2</issue>), <fpage>283</fpage>–<lpage>297</lpage>.<pub-id pub-id-type="pmid">12873385</pub-id></mixed-citation>
</ref>
<ref id="humu23647-bib-0010">
<mixed-citation id="humu23647-cit-0010" publication-type="journal">
<string-name>
<surname>Fong</surname>, <given-names>Y. L.</given-names>
</string-name>, <string-name>
<surname>Taylor</surname>, <given-names>W. L.</given-names>
</string-name>, <string-name>
<surname>Means</surname>, <given-names>A. R.</given-names>
</string-name>, &amp; <string-name>
<surname>Soderling</surname>, <given-names>T. R.</given-names>
</string-name> (<year>1989</year>). <article-title>Studies of the regulatory mechanism of Ca<sup>2+</sup>/calmodulin‐dependent protein kinase II. Mutation of threonine 286 to alanine and aspartate</article-title>. <source xml:lang="en"/>The Journal of Biological Chemistry, <volume>264</volume>(<issue>28</issue>), <fpage>16759</fpage>–<lpage>16763</lpage>.<pub-id pub-id-type="pmid">2550458</pub-id></mixed-citation>
</ref>
<ref id="humu23647-bib-0011">
<mixed-citation id="humu23647-cit-0011" publication-type="journal">
<string-name>
<surname>Giese</surname>, <given-names>K. P.</given-names>
</string-name>, <string-name>
<surname>Fedorov</surname>, <given-names>N. B.</given-names>
</string-name>, <string-name>
<surname>Filipkowski</surname>, <given-names>R. K.</given-names>
</string-name>, &amp; <string-name>
<surname>Silva</surname>, <given-names>A. J.</given-names>
</string-name> (<year>1998</year>). <article-title>Autophosphorylation at Thr286 of the alpha calcium‐calmodulin kinase II in LTP and learning</article-title>. <source xml:lang="en"/>Science, <volume>279</volume>(<issue>5352</issue>), <fpage>870</fpage>–<lpage>873</lpage>.<pub-id pub-id-type="pmid">9452388</pub-id></mixed-citation>
</ref>
<ref id="humu23647-bib-0012">
<mixed-citation id="humu23647-cit-0012" publication-type="book">
<string-name>
<surname>Goslin</surname>, <given-names>K.</given-names>
</string-name>, &amp; <string-name>
<surname>Banker</surname>, <given-names>G.</given-names>
</string-name> (<year>1991</year>). <source xml:lang="en"/>Culturing nerve cells. <publisher-name>MIT Press</publisher-name>: <publisher-name>Cambridge</publisher-name>, pp. <fpage>251</fpage>–<lpage>281</lpage>.</mixed-citation>
</ref>
<ref id="humu23647-bib-0013">
<mixed-citation id="humu23647-cit-0013" publication-type="journal">
<string-name>
<surname>Hanson</surname>, <given-names>P. I.</given-names>
</string-name>, <string-name>
<surname>Kapiloff</surname>, <given-names>M. S.</given-names>
</string-name>, <string-name>
<surname>Lou</surname>, <given-names>L. L.</given-names>
</string-name>, <string-name>
<surname>Rosenfeld</surname>, <given-names>M. G.</given-names>
</string-name>, &amp; <string-name>
<surname>Schulman</surname>, <given-names>H.</given-names>
</string-name> (<year>1989</year>). <article-title>Expression of a multifunctional Ca<sup>2+</sup>/calmodulin‐dependent protein kinase and mutational analysis of its autoregulation</article-title>. <source xml:lang="en"/>Neuron, <volume>3</volume>(<issue>1</issue>), <fpage>59</fpage>–<lpage>70</lpage>.<pub-id pub-id-type="pmid">2619995</pub-id></mixed-citation>
</ref>
<ref id="humu23647-bib-0014">
<mixed-citation id="humu23647-cit-0014" publication-type="journal">
<string-name>
<surname>Hanson</surname>, <given-names>P. I.</given-names>
</string-name>, <string-name>
<surname>Meyer</surname>, <given-names>T.</given-names>
</string-name>, <string-name>
<surname>Stryer</surname>, <given-names>L.</given-names>
</string-name>, &amp; <string-name>
<surname>Schulman</surname>, <given-names>H.</given-names>
</string-name> (<year>1994</year>). <article-title>Dual role of calmodulin in autophosphorylation of multifunctional CaM kinase may underlie decoding of calcium signals</article-title>. <source xml:lang="en"/>Neuron, <volume>12</volume>(<issue>5</issue>), <fpage>943</fpage>–<lpage>956</lpage>.<pub-id pub-id-type="pmid">8185953</pub-id></mixed-citation>
</ref>
<ref id="humu23647-bib-0015">
<mixed-citation id="humu23647-cit-0015" publication-type="journal">
<string-name>
<surname>Heist</surname>, <given-names>E. K.</given-names>
</string-name>, <string-name>
<surname>Srinivasan</surname>, <given-names>M.</given-names>
</string-name>, &amp; <string-name>
<surname>Schulman</surname>, <given-names>H.</given-names>
</string-name> (<year>1998</year>). <article-title>Phosphorylation at the nuclear localization signal of Ca2+/calmodulin‐dependent protein kinase II blocks its nuclear targeting</article-title>. <source xml:lang="en"/>The Journal of Biological Chemistry, <volume>273</volume>(<issue>31</issue>), <fpage>19763</fpage>–<lpage>19771</lpage>.<pub-id pub-id-type="pmid">9677407</pub-id></mixed-citation>
</ref>
<ref id="humu23647-bib-0016">
<mixed-citation id="humu23647-cit-0016" publication-type="journal">
<string-name>
<surname>Hell</surname>, <given-names>J. W.</given-names>
</string-name> (<year>2014</year>). <article-title>CaMKII: Claiming center stage in postsynaptic function and organization</article-title>. <source xml:lang="en"/>Neuron, <volume>81</volume>(<issue>2</issue>), <fpage>249</fpage>–<lpage>265</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuron.2013.12.024</pub-id>
<pub-id pub-id-type="pmid">24462093</pub-id></mixed-citation>
</ref>
<ref id="humu23647-bib-0017">
<mixed-citation id="humu23647-cit-0017" publication-type="journal">
<string-name>
<surname>Hudmon</surname>, <given-names>A.</given-names>
</string-name>, &amp; <string-name>
<surname>Schulman</surname>, <given-names>H.</given-names>
</string-name> (<year>2002</year>). <article-title>Neuronal Ca<sup>2+</sup>/calmodulin‐dependent protein kinase II: The role of structure and autoregulation in cellular function</article-title>. <source xml:lang="en"/>Annual Review of Biochemistry, <volume>71</volume>, <fpage>473</fpage>–<lpage>510</lpage>. <pub-id pub-id-type="doi">10.1146/annurev.biochem.71.110601.135410</pub-id>
</mixed-citation>
</ref>
<ref id="humu23647-bib-0018">
<mixed-citation id="humu23647-cit-0018" publication-type="journal">
<string-name>
<surname>Küry</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>van Woerden</surname>, <given-names>G. M.</given-names>
</string-name>, <string-name>
<surname>Besnard</surname>, <given-names>T.</given-names>
</string-name>, <string-name>
<surname>Proietti Onori</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Latypova</surname>, <given-names>X.</given-names>
</string-name>, … <string-name>
<surname>Towne</surname>, <given-names>M. C.</given-names>
</string-name> (<year>2017</year>). <article-title>De novo mutations in protein kinase genes CAMK2A and CAMK2B cause intellectual disability</article-title>. <source xml:lang="en"/>American Journal of Human Genetics, <volume>101</volume>(<issue>5</issue>), <fpage>768</fpage>–<lpage>788</lpage>. <pub-id pub-id-type="doi">10.1016/j.ajhg.2017.10.003</pub-id>
<pub-id pub-id-type="pmid">29100089</pub-id></mixed-citation>
</ref>
<ref id="humu23647-bib-0019">
<mixed-citation id="humu23647-cit-0019" publication-type="journal">
<string-name>
<surname>Li</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Zhou</surname>, <given-names>T.</given-names>
</string-name>, <string-name>
<surname>Liao</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Yang</surname>, <given-names>Z.</given-names>
</string-name>, <string-name>
<surname>Wong</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Henn</surname>, <given-names>F.</given-names>
</string-name>, … <string-name>
<surname>Hu</surname>, <given-names>H.</given-names>
</string-name> (<year>2013</year>). <article-title>βCaMKII in lateral habenula mediates core symptoms of depression</article-title>. <source xml:lang="en"/>Science, <volume>341</volume>(<issue>6149</issue>), <fpage>1016</fpage>–<lpage>1020</lpage>. <pub-id pub-id-type="doi">10.1126/science.1240729</pub-id>
<pub-id pub-id-type="pmid">23990563</pub-id></mixed-citation>
</ref>
<ref id="humu23647-bib-0020">
<mixed-citation id="humu23647-cit-0020" publication-type="journal">
<string-name>
<surname>Lisman</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Schulman</surname>, <given-names>H.</given-names>
</string-name>, &amp; <string-name>
<surname>Cline</surname>, <given-names>H.</given-names>
</string-name> (<year>2002</year>). <article-title>The molecular basis of CaMKII function in synaptic and behavioural memory</article-title>. <source xml:lang="en"/>Nature Reviews. Neuroscience, <volume>3</volume>(<issue>3</issue>), <fpage>175</fpage>–<lpage>190</lpage>. <pub-id pub-id-type="doi">10.1038/nrn753</pub-id>
<pub-id pub-id-type="pmid">11994750</pub-id></mixed-citation>
</ref>
<ref id="humu23647-bib-0021">
<mixed-citation id="humu23647-cit-0021" publication-type="journal">
<string-name>
<surname>Lisman</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Yasuda</surname>, <given-names>R.</given-names>
</string-name>, &amp; <string-name>
<surname>Raghavachari</surname>, <given-names>S.</given-names>
</string-name> (<year>2012</year>). <article-title>Mechanisms of CaMKII action in long‐term potentiation</article-title>. <source xml:lang="en"/>Nature Reviews. Neuroscience., <pub-id pub-id-type="doi">10.1038/nrn3192</pub-id>
</mixed-citation>
</ref>
<ref id="humu23647-bib-0022">
<mixed-citation id="humu23647-cit-0022" publication-type="journal">
<string-name>
<surname>Ma</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<surname>Groth</surname>, <given-names>R. D.</given-names>
</string-name>, <string-name>
<surname>Cohen</surname>, <given-names>S. M.</given-names>
</string-name>, <string-name>
<surname>Emery</surname>, <given-names>J. F.</given-names>
</string-name>, <string-name>
<surname>Li</surname>, <given-names>B.</given-names>
</string-name>, <string-name>
<surname>Hoedt</surname>, <given-names>E.</given-names>
</string-name>, … <string-name>
<surname>Tsien</surname>, <given-names>R.W.</given-names>
</string-name> (<year>2014</year>). <article-title>γCaMKII shuttles Ca²⁺/CaM to the nucleus to trigger CREB phosphorylation and gene expression</article-title>. <source xml:lang="en"/>Cell, <volume>159</volume>(<issue>2</issue>), <fpage>281</fpage>–<lpage>294</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2014.09.019</pub-id>
<pub-id pub-id-type="pmid">25303525</pub-id></mixed-citation>
</ref>
<ref id="humu23647-bib-0023">
<mixed-citation id="humu23647-cit-0023" publication-type="journal">
<string-name>
<surname>Mayford</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Wang</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Kandel</surname>, <given-names>E. R.</given-names>
</string-name>, &amp; <string-name>
<surname>O'Dell</surname>, <given-names>T. J.</given-names>
</string-name> (<year>1995</year>). <article-title>CaMKII regulates the frequency‐response function of hippocampal synapses for the production of both LTD and LTP</article-title>. <source xml:lang="en"/>Cell, <volume>81</volume>(<issue>6</issue>), <fpage>891</fpage>–<lpage>904</lpage>.<pub-id pub-id-type="pmid">7781066</pub-id></mixed-citation>
</ref>
<ref id="humu23647-bib-0024">
<mixed-citation id="humu23647-cit-0024" publication-type="journal">
<string-name>
<surname>Ohsako</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Nakazawa</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<surname>Sekihara</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Ikai</surname>, <given-names>A.</given-names>
</string-name>, &amp; <string-name>
<surname>Yamauchi</surname>, <given-names>T.</given-names>
</string-name> (<year>1991</year>). <article-title>Role of threonine‐286 as autophosphorylation site for appearance of Ca2(+)‐independent activity of calmodulin‐dependent protein kinase II alpha subunit</article-title>. <source xml:lang="en"/>Journal of Biochemistry, <volume>109</volume>(<issue>1</issue>), <fpage>137</fpage>–<lpage>143</lpage>.<pub-id pub-id-type="pmid">1849884</pub-id></mixed-citation>
</ref>
<ref id="humu23647-bib-0025">
<mixed-citation id="humu23647-cit-0025" publication-type="journal">
<string-name>
<surname>Pan</surname>, <given-names>Z.</given-names>
</string-name>, <string-name>
<surname>Zhu</surname>, <given-names>L.‐J.</given-names>
</string-name>, <string-name>
<surname>Li</surname>, <given-names>Y.‐Q.</given-names>
</string-name>, <string-name>
<surname>Hao</surname>, <given-names>L.‐Y.</given-names>
</string-name>, <string-name>
<surname>Yin</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Yang</surname>, <given-names>J.‐X.</given-names>
</string-name>, … <string-name>
<surname>Cao</surname>
<given-names>J. L.</given-names>
</string-name> (<year>2014</year>). <article-title>Epigenetic modification of spinal miR‐219 expression regulates chronic inflammation pain by targeting CaMKIIγ</article-title>. <source xml:lang="en"/>The Journal of Neuroscience: The Official Journal of the Society for Neuroscience, <volume>34</volume>(<issue>29</issue>), <fpage>9476</fpage>–<lpage>9483</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.5346-13.2014</pub-id>
<pub-id pub-id-type="pmid">25031391</pub-id></mixed-citation>
</ref>
<ref id="humu23647-bib-0026">
<mixed-citation id="humu23647-cit-0026" publication-type="journal">
<string-name>
<surname>Payne</surname>, <given-names>M. E.</given-names>
</string-name>, <string-name>
<surname>Fong</surname>, <given-names>Y. L.</given-names>
</string-name>, <string-name>
<surname>Ono</surname>, <given-names>T.</given-names>
</string-name>, <string-name>
<surname>Colbran</surname>, <given-names>R. J.</given-names>
</string-name>, <string-name>
<surname>Kemp</surname>, <given-names>B. E.</given-names>
</string-name>, <string-name>
<surname>Soderling</surname>, <given-names>T. R.</given-names>
</string-name>, &amp; <string-name>
<surname>Means</surname>, <given-names>A. R.</given-names>
</string-name> (<year>1988</year>). <article-title>Calcium/calmodulin‐dependent protein kinase II. Characterization of distinct calmodulin binding and inhibitory domains</article-title>. <source xml:lang="en"/>The Journal of Biological Chemistry, <volume>263</volume>(<issue>15</issue>), <fpage>7190</fpage>–<lpage>7195</lpage>.<pub-id pub-id-type="pmid">2835367</pub-id></mixed-citation>
</ref>
<ref id="humu23647-bib-0027">
<mixed-citation id="humu23647-cit-0027" publication-type="journal">
<string-name>
<surname>Pi</surname>, <given-names>H. J.</given-names>
</string-name>, <string-name>
<surname>Otmakhov</surname>, <given-names>N.</given-names>
</string-name>, <string-name>
<surname>Gaamouch, El</surname>, <given-names>F.</given-names>
</string-name>, <string-name>
<surname>Lemelin</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>De Koninck</surname>, <given-names>P.</given-names>
</string-name>, &amp; <string-name>
<surname>Lisman</surname>, <given-names>J.</given-names>
</string-name> (<year>2010a</year>). <article-title>CaMKII control of spine size and synaptic strength: Role of phosphorylation states and nonenzymatic action</article-title>. <source xml:lang="en"/>Proceedings of the National Academy of Sciences of the United States of America, <volume>107</volume>(<issue>32</issue>), <fpage>14437</fpage>–<lpage>14442</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1009268107</pub-id>
<pub-id pub-id-type="pmid">20660727</pub-id></mixed-citation>
</ref>
<ref id="humu23647-bib-0028">
<mixed-citation id="humu23647-cit-0028" publication-type="journal">
<string-name>
<surname>Pi</surname>, <given-names>H. J.</given-names>
</string-name>, <string-name>
<surname>Otmakhov</surname>, <given-names>N.</given-names>
</string-name>, <string-name>
<surname>Lemelin</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>De Koninck</surname>, <given-names>P.</given-names>
</string-name>, &amp; <string-name>
<surname>Lisman</surname>, <given-names>J.</given-names>
</string-name> (<year>2010b</year>). <article-title>Autonomous CaMKII can promote either long‐term potentiation or long‐term depression, Depending on the state of T305/T306 phosphorylation</article-title>. <source xml:lang="en"/>The Journal of Neuroscience: The Official Journal of the Society for Neuroscience, <volume>30</volume>(<issue>26</issue>), <fpage>8704</fpage>–<lpage>8709</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.0133-10.2010</pub-id>
<pub-id pub-id-type="pmid">20592192</pub-id></mixed-citation>
</ref>
<ref id="humu23647-bib-0029">
<mixed-citation id="humu23647-cit-0029" publication-type="journal">
<string-name>
<surname>Rellos</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<surname>Pike</surname>, <given-names>A. C. W.</given-names>
</string-name>, <string-name>
<surname>Niesen</surname>, <given-names>F. H.</given-names>
</string-name>, <string-name>
<surname>Salah</surname>, <given-names>E.</given-names>
</string-name>, <string-name>
<surname>Lee</surname>, <given-names>W. H.</given-names>
</string-name>, <string-name>
<surname>Delft, von</surname>, <given-names>F.</given-names>
</string-name>, &amp; <string-name>
<surname>Knapp</surname>, <given-names>S.</given-names>
</string-name> (<year>2010</year>). <article-title>Structure of the CaMKIIdelta/calmodulin complex reveals the molecular mechanism of CaMKII kinase activation</article-title>. <source xml:lang="en"/>PLoS Biology, <volume>8</volume>(<issue>7</issue>), <fpage>e1000426</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pbio.1000426</pub-id>
<pub-id pub-id-type="pmid">20668654</pub-id></mixed-citation>
</ref>
<ref id="humu23647-bib-0030">
<mixed-citation id="humu23647-cit-0030" publication-type="journal">
<string-name>
<surname>Saito</surname>, <given-names>T.</given-names>
</string-name> (<year>2006</year>). <article-title>In vivo electroporation in the embryonic mouse central nervous system</article-title>. <source xml:lang="en"/>Nature Protocols, <volume>1</volume>(<issue>3</issue>), <fpage>1552</fpage>–<lpage>1558</lpage>. <pub-id pub-id-type="doi">10.1038/nprot.2006.276</pub-id>
<pub-id pub-id-type="pmid">17406448</pub-id></mixed-citation>
</ref>
<ref id="humu23647-bib-0031">
<mixed-citation id="humu23647-cit-0031" publication-type="journal">
<string-name>
<surname>Saito</surname>, <given-names>T.</given-names>
</string-name>, &amp; <string-name>
<surname>Nakatsuji</surname>, <given-names>N.</given-names>
</string-name> (<year>2001</year>). <article-title>Efficient gene transfer into the embryonic mouse brain using in vivo electroporation</article-title>. <source xml:lang="en"/>Developmental Biology, <volume>240</volume>(<issue>1</issue>), <fpage>237</fpage>–<lpage>246</lpage>. <pub-id pub-id-type="doi">10.1006/dbio.2001.0439</pub-id>
<pub-id pub-id-type="pmid">11784059</pub-id></mixed-citation>
</ref>
<ref id="humu23647-bib-0032">
<mixed-citation id="humu23647-cit-0032" publication-type="journal">
<string-name>
<surname>Shen</surname>, <given-names>K.</given-names>
</string-name>, &amp; <string-name>
<surname>Meyer</surname>, <given-names>T.</given-names>
</string-name> (<year>1999</year>). <article-title>Dynamic control of CaMKII translocation and localization in hippocampal neurons by NMDA receptor stimulation</article-title>. <source xml:lang="en"/>Science, <volume>284</volume>(<issue>5411</issue>), <fpage>162</fpage>–<lpage>166</lpage>. <pub-id pub-id-type="doi">10.1126/science.284.5411.162</pub-id>
<pub-id pub-id-type="pmid">10102820</pub-id></mixed-citation>
</ref>
<ref id="humu23647-bib-0033">
<mixed-citation id="humu23647-cit-0033" publication-type="journal">
<string-name>
<surname>Shioda</surname>, <given-names>N.</given-names>
</string-name>, <string-name>
<surname>Sawai</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Ishizuka</surname>, <given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Shirao</surname>, <given-names>T.</given-names>
</string-name>, &amp; <string-name>
<surname>Fukunaga</surname>, <given-names>K.</given-names>
</string-name> (<year>2015</year>). <article-title>Nuclear translocation of calcium/calmodulin‐dependent protein kinase IIδ3 promoted by protein phosphatase‐1 enhances brain‐derived neurotrophic factor expression in dopaminergic neurons</article-title>. <source xml:lang="en"/>Journal of Biological Chemistry, <volume>290</volume>(<issue>35</issue>), <fpage>21663</fpage>–<lpage>21675</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M115.664920</pub-id>
<pub-id pub-id-type="pmid">26163515</pub-id></mixed-citation>
</ref>
<ref id="humu23647-bib-0034">
<mixed-citation id="humu23647-cit-0034" publication-type="journal">
<string-name>
<surname>Silva</surname>, <given-names>A. J.</given-names>
</string-name>, <string-name>
<surname>Paylor</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Wehner</surname>, <given-names>J. M.</given-names>
</string-name>, &amp; <string-name>
<surname>Tonegawa</surname>, <given-names>S.</given-names>
</string-name> (<year>1992a</year>). <article-title>Impaired spatial learning in alpha‐calcium‐calmodulin kinase II mutant mice</article-title>. <source xml:lang="en"/>Science, <volume>257</volume>(<issue>5067</issue>), <fpage>206</fpage>–<lpage>211</lpage>.<pub-id pub-id-type="pmid">1321493</pub-id></mixed-citation>
</ref>
<ref id="humu23647-bib-0035">
<mixed-citation id="humu23647-cit-0035" publication-type="journal">
<string-name>
<surname>Silva</surname>, <given-names>A. J.</given-names>
</string-name>, <string-name>
<surname>Stevens</surname>, <given-names>C. F.</given-names>
</string-name>, <string-name>
<surname>Tonegawa</surname>, <given-names>S.</given-names>
</string-name>, &amp; <string-name>
<surname>Wang</surname>, <given-names>Y.</given-names>
</string-name> (<year>1992b</year>). <article-title>Deficient hippocampal long‐term potentiation in alpha‐calcium‐calmodulin kinase II mutant mice</article-title>. <source xml:lang="en"/>Science, <volume>257</volume>(<issue>5067</issue>), <fpage>201</fpage>–<lpage>206</lpage>.<pub-id pub-id-type="pmid">1378648</pub-id></mixed-citation>
</ref>
<ref id="humu23647-bib-0036">
<mixed-citation id="humu23647-cit-0036" publication-type="journal">
<string-name>
<surname>Smith</surname>, <given-names>M. K.</given-names>
</string-name>, <string-name>
<surname>Colbran</surname>, <given-names>R. J.</given-names>
</string-name>, <string-name>
<surname>Brickey</surname>, <given-names>D. A.</given-names>
</string-name>, &amp; <string-name>
<surname>Soderling</surname>, <given-names>T. R.</given-names>
</string-name> (<year>1992</year>). <article-title>Functional determinants in the autoinhibitory domain of calcium/calmodulin‐dependent protein kinase II. Role of His282 and multiple basic residues</article-title>. <source xml:lang="en"/>The Journal of Biological Chemistry, <volume>267</volume>(<issue>3</issue>), <fpage>1761</fpage>–<lpage>1768</lpage>.<pub-id pub-id-type="pmid">1309796</pub-id></mixed-citation>
</ref>
<ref id="humu23647-bib-0037">
<mixed-citation id="humu23647-cit-0037" publication-type="journal">
<string-name>
<surname>Tabata</surname>, <given-names>H.</given-names>
</string-name>, &amp; <string-name>
<surname>Nakajima</surname>, <given-names>K.</given-names>
</string-name> (<year>2001</year>). <article-title>Efficient <italic>in utero</italic> gene transfer system to the developing mouse brain using electroporation: Visualization of neuronal migration in the developing cortex</article-title>. <source xml:lang="en"/>Neuroscience, <volume>103</volume>(<issue>4</issue>), <fpage>865</fpage>–<lpage>872</lpage>.<pub-id pub-id-type="pmid">11301197</pub-id></mixed-citation>
</ref>
<ref id="humu23647-bib-0038">
<mixed-citation id="humu23647-cit-0038" publication-type="journal">
<string-name>
<surname>Takeuchi</surname>, <given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Fukunaga</surname>, <given-names>K.</given-names>
</string-name>, &amp; <string-name>
<surname>Miyamoto</surname>, <given-names>E.</given-names>
</string-name> (<year>2002</year>). <article-title>Activation of nuclear Ca(2+)/calmodulin‐dependent protein kinase II and brain‐derived neurotrophic factor gene expression by stimulation of dopamine D2 receptor in transfected NG108‐15 cells</article-title>. <source xml:lang="en"/>Journal of Neurochemistry, <volume>82</volume>(<issue>2</issue>), <fpage>316</fpage>–<lpage>328</lpage>.<pub-id pub-id-type="pmid">12124432</pub-id></mixed-citation>
</ref>
<ref id="humu23647-bib-0039">
<mixed-citation id="humu23647-cit-0039" publication-type="journal">
<string-name>
<surname>Taniguchi</surname>, <given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Young‐Pearse</surname>, <given-names>T.</given-names>
</string-name>, <string-name>
<surname>Sawa</surname>, <given-names>A.</given-names>
</string-name>, &amp; <string-name>
<surname>Kamiya</surname>, <given-names>A.</given-names>
</string-name> (<year>2012</year>). <article-title>In utero electroporation as a tool for genetic manipulation in vivo to study psychiatric disorders: From genes to circuits and behaviors</article-title>. <source xml:lang="en"/>The Neuroscientist, <volume>18</volume>(<issue>2</issue>), <fpage>169</fpage>–<lpage>179</lpage>. <pub-id pub-id-type="doi">10.1177/1073858411399925</pub-id>
<pub-id pub-id-type="pmid">21551077</pub-id></mixed-citation>
</ref>
<ref id="humu23647-bib-0040">
<mixed-citation id="humu23647-cit-0040" publication-type="journal">
<string-name>
<surname>Tobimatsu</surname>, <given-names>T.</given-names>
</string-name>, &amp; <string-name>
<surname>Fujisawa</surname>, <given-names>H.</given-names>
</string-name> (<year>1989</year>). <article-title>Tissue‐specific expression of four types of rat calmodulin‐dependent protein kinase II mRNAs</article-title>. <source xml:lang="en"/>The Journal of Biological Chemistry, <volume>264</volume>(<issue>30</issue>), <fpage>17907</fpage>–<lpage>17912</lpage>.<pub-id pub-id-type="pmid">2553697</pub-id></mixed-citation>
</ref>
<ref id="humu23647-bib-0041">
<mixed-citation id="humu23647-cit-0041" publication-type="journal">
<string-name>
<surname>van Woerden</surname>, <given-names>G. M.</given-names>
</string-name>, <string-name>
<surname>Hoebeek</surname>, <given-names>F. E.</given-names>
</string-name>, <string-name>
<surname>Gao</surname>, <given-names>Z.</given-names>
</string-name>, <string-name>
<surname>Nagaraja</surname>, <given-names>R. Y.</given-names>
</string-name>, <string-name>
<surname>Hoogenraad</surname>, <given-names>C. C.</given-names>
</string-name>, <string-name>
<surname>Kushner</surname>, <given-names>S. A.</given-names>
</string-name>, … <string-name>
<surname>Elgersma</surname>, <given-names>Y.</given-names>
</string-name> (<year>2009</year>). <article-title>betaCaMKII controls the direction of plasticity at parallel fiber‐Purkinje cell synapses</article-title>. <source xml:lang="en"/>Nature Neuroscience, <volume>12</volume>(<issue>7</issue>), <fpage>823</fpage>–<lpage>825</lpage>. <pub-id pub-id-type="doi">10.1038/nn.2329</pub-id>
<pub-id pub-id-type="pmid">19503086</pub-id></mixed-citation>
</ref>
<ref id="humu23647-bib-0042">
<mixed-citation id="humu23647-cit-0042" publication-type="journal">
<string-name>
<surname>Vissers</surname>, <given-names>L. E. L. M.</given-names>
</string-name>, <string-name>
<surname>Gilissen</surname>, <given-names>C.</given-names>
</string-name>, &amp; <string-name>
<surname>Veltman</surname>, <given-names>J. A.</given-names>
</string-name> (<year>2016</year>). <article-title>Genetic studies in intellectual disability and related disorders</article-title>. <source xml:lang="en"/>Nature Reviews. Genetics, <volume>17</volume>(<issue>1</issue>), <fpage>9</fpage>–<lpage>18</lpage>. <pub-id pub-id-type="doi">10.1038/nrg3999</pub-id>
</mixed-citation>
</ref>
<ref id="humu23647-bib-0043">
<mixed-citation id="humu23647-cit-0043" publication-type="journal">
<string-name>
<surname>Waldmann</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Hanson</surname>, <given-names>P. I.</given-names>
</string-name>, &amp; <string-name>
<surname>Schulman</surname>, <given-names>H.</given-names>
</string-name> (<year>1990</year>). <article-title>Multifunctional Ca2+/calmodulin‐dependent protein kinase made Ca2+ independent for functional studies</article-title>. <source xml:lang="en"/>Biochemistry, <volume>29</volume>(<issue>7</issue>), <fpage>1679</fpage>–<lpage>1684</lpage>.<pub-id pub-id-type="pmid">2158811</pub-id></mixed-citation>
</ref>
<ref id="humu23647-bib-0044">
<mixed-citation id="humu23647-cit-0044" publication-type="journal">
<string-name>
<surname>Waxham</surname>, <given-names>M. N.</given-names>
</string-name>, <string-name>
<surname>Aronowski</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Westgate</surname>, <given-names>S. A.</given-names>
</string-name>, &amp; <string-name>
<surname>Kelly</surname>, <given-names>P. T.</given-names>
</string-name> (<year>1990</year>). <article-title>Mutagenesis of Thr‐286 in monomeric Ca<sup>2+</sup>/calmodulin‐dependent protein kinase II eliminates Ca<sup>2+</sup>/calmodulin‐independent activity</article-title>. <source xml:lang="en"/>Proceedings of the National Academy of Sciences of the United States of America, <volume>87</volume>(<issue>4</issue>), <fpage>1273</fpage>–<lpage>1277</lpage>.<pub-id pub-id-type="pmid">2154738</pub-id></mixed-citation>
</ref>
<ref id="humu23647-bib-0045">
<mixed-citation id="humu23647-cit-0045" publication-type="journal">
<string-name>
<surname>Yang</surname>, <given-names>E.</given-names>
</string-name>, &amp; <string-name>
<surname>Schulman</surname>, <given-names>H.</given-names>
</string-name> (<year>1999</year>). <article-title>Structural examination of autoregulation of multifunctional calcium/calmodulin‐dependent protein kinase II</article-title>. <source xml:lang="en"/>The Journal of Biological Chemistry, <volume>274</volume>(<issue>37</issue>), <fpage>26199</fpage>–<lpage>26208</lpage>.<pub-id pub-id-type="pmid">10473573</pub-id></mixed-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>